Results of network meta-analysis

Contents

Tables

Figures

Living at home available care network, short-term timeframe

Table 1 - Short-term living at home available-care network

Study	Frailty	n	Experimental group	Control group	ROB D1	D2	D3	D4	D5	Overall
Challis 2004[1]	frail	256	mfar(w/med)	mfar	-	-	+	+	+	-
Imhof 2012[2]	all	448	mfar	ac	-	-	+	+	-	-
Kukkonen-Harjula 2017[3]	pre-frail and frail	292	ADL & ntr & exrc	ac	+	-	+	+	-	-
Liddle 1996[4]	unclassifiable	105	aids & mfar	ac	-	x	+	+	-	xx
Metzelthin 2013[5]	frail	341	educ & mfar(w/med+slfm)	ac	-/-	-	+	+	-	-
Suijker 2016[6]	frail	2031	mfar(w/med)	ac	+/-	-	-	+	-	-
Szanton 2011[7]	pre-frail and frail	39	ADL&aids&educ&exrc& mfar(w/med+slfm)	ac	-	-	+	+	-	-
Wong 2019[8]	all	501	mfar(w/slfm)	ac	x	-	-	+	-	x

Table 2 - Results of living at home: short-term available care network

mfar(w/slfm)							1.34 (0.56,3.25)
1.42 (0.52,3.90)	**mfar(w/med)**	0.62 (0.38,1.02)					1.11 (0.63,1.95)
1.00 (0.35,2.89)	0.71 (0.45,1.11)	**mfar**					0.87 (0.35,2.19)
2.57 (0.50,13.10)	1.81 (0.42,7.76)	2.56 (0.58,11.33)	**educ & mfar(w/med+slfm)**				0.52 (0.13,2.06)
0.44 (0.04,5.14)	0.31 (0.03,3.24)	0.44 (0.04,4.68)	0.17 (0.01,2.48)	**aids & mfar**			3.06 (0.31,30.42)
7.58 (0.32,178.38)	5.34 (0.25,115.36)	7.55 (0.34,165.59)	2.95 (0.11,82.25)	17.24 (0.38,774.20)	**ADL&aids&ed&ex&mf(w/med+slfm)**		0.18 (0.01,3.69)
1.33 (0.25,6.97)	0.93 (0.21,4.14)	1.32 (0.29,6.04)	0.52 (0.07,3.67)	3.02 (0.20,44.55)	0.18 (0.01,4.95)	**ADL & ntr & exrc**	1.01 (0.25,4.13)
1.34 (0.56,3.25)	0.95 (0.58,1.55)	1.34 (0.75,2.39)	0.52 (0.13,2.06)	3.06 (0.31,30.42)	0.18 (0.01,3.69)	1.01 (0.25,4.13)	**ac**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR>1 favours the upper left intervention; a OR<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 3 - Intervention rankings for living at home: short-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
aids & mfar	82.8	63.9	2.2	1	7
mfar	70.3	9.2	3.1	1	6
mfar(w/slfm)	66	13	3.4	1	7
adl & ntr & exrc	50.5	8.2	4.5	1	8
ac	47.7	0.4	4.7	2	7
mfar(w/med)	43.5	0.2	5	2	7
educ & mfar(w/med+slfm)	25.5	1.4	6.2	2	8
adl&aids&ed&ex&mf(w/med+slfm)	13.6	3.7	7	1	8

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.

Living at home available care network, medium-term timeframe

Table 4 - Medium-term living at home available-care network

					ROB					
Study	Frailty	n	Experimental group	Control group	D1	D2	D3	D4	D5	Overall
Blom 2016[9]	all	1105	mfa-(w/med+slfm)	ac	x/+	-	x	+	-	xx
Dalby 2000[10]	frail	139	mfar(w/med)	ac	-	-	+	+	+	-
Fabacher 1994[11]	all	229	mfar(w/med)	ac	-	-	x	+	+	x
Hall 1992[12]	frail	167	hmcr & mfar(w/slfm)	hmcr & mfar	-	-	+	+	+	-
Harari 2008[13]	all	2425	mfar(w/med)	ac	+	x	+	+	-	x
Hay 1998[14]	unclassifiable	485	mfa-	ac	-	-	x	+	-	x
Hebert 2001[15]	pre-frail and frail	494	mfar(w/med)	ac	-	-	+	+	-	-
Henderson 2005[16]	robust	136	mfar	ac	+/x	+	x	+	-	xx
Kerse 2014[17]	pre-frail and frail	3712	rsk-mfa-	ac	+/+	-	+	+	-	-
Kono 2004[18]	pre-frail and frail	117	mfar	ac	-	-	+	+	-	-
Kono 2016[19]	pre-frail	313	mfar(w/med)	mfar	+	-	-	+	+	-
Kukkonen-Harjula 2017[3]	pre-frail and frail	287	ADL & ntr & exrc	ac	+	-	+	+	-	-
Metzelthin 2013[5]	frail	325	educ & mfar(w/med+slfm)	ac	-/-	-	-	+	-	-
Monteserin Nadal 2008[20]	all	516	educ & rsk-mfa-	ac	-	-	x	+	+	x
Newbury 2001[21]	unclassifiable	100	mfa-(w/med)	ac	-	-	+	+	-	-
Newcomer 2004[22]	unclassifiable	2934	educ & mfar(w/med)	ac	-	-	+	+	-	-
Ploeg 2010[23]	pre-frail and frail	665	educ & mfar(w/med)	ac	+	-	x	+	-	x
Romera-Liebana 2018[24]	pre-frail and frail	342	cgn & med & ntr & exrc	ac	+	-	+	+	-	-
Shapiro 2002[25]	frail	72	hmcr & mfar	ac	-	x	x	+	-	xx
Suijker 2016[6]	frail	1873	mfar(w/med)	ac	+/-	-	-	+	-	-
van Hout 2010[26]	frail	501	mfar(w/med)	ac	+	-	x	+	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 5 - Results of living at home: medium-term available care network

rsk-mfa-													0.90 (0.70,1.17)
0.74 (0.49,1.11)	**mfar(w/med)**	1.22 (0.36, 4.07)											1.22 (0.96, 1.56)
0.79 (0.39,1.60)	1.06 (0.55,2.06)	**mfar**											1.18 (0.50, 2.79)
0.90 (0.52,1.57)	1.22 (0.72,2.07)	1.15 (0.52,2.53)	**mfa-(w/med+slfm)**										1.00 (0.65, 1.53)
0.35 (0.08,1.52)	0.48 (0.11,2.04)	0.45 (0.09,2.15)	0.39 (0.09,1.75)	**mfa-(w/med)**									2.55 (0.62, 10.49)
0.41 (0.11,1.49)	0.55 (0.15,2.00)	0.52 (0.12,2.13)	0.45 (0.12,1.73)	1.14 (0.17,7.69)	**mfa-**								2.23 (0.64, 7.82)
0.10 (0.02,0.49)	0.14 (0.03,0.66)	0.13 (0.02,0.69)	0.11 (0.02,0.56)	0.29 (0.04,2.34)	0.25 (0.03,1.85)	**hmcr & mfar(w/slfm)**	1.56 (0.63, 3.82)						
0.16 (0.04,0.57)	0.21 (0.06,0.76)	0.20 (0.05,0.81)	0.18 (0.05,0.66)	0.45 (0.07,2.96)	0.39 (0.07,2.30)	1.56 (0.62,3.88)	**hmcr & mfar**						5.71 (1.67, 19.60)
0.83 (0.42,1.63)	1.12 (0.58,2.17)	1.05 (0.43,2.54)	0.92 (0.43,1.96)	2.33 (0.50,10.98)	2.04 (0.50,8.31)	8.13 (1.55,42.75)	5.23 (1.31,20.88)	**educ & rsk-mfa-**					1.09 (0.61, 1.96)
2.22 (0.74,6.69)	3.00 (1.01,8.93)	2.82 (0.82,9.73)	2.46 (0.78,7.79)	6.26 (1.06,36.96)	5.48 (1.05,28.53)	21.84 (3.36,141.97)	14.04 (2.74,71.90)	2.68 (0.79,9.10)	**educ & mfar(w/med+slfm)**				0.41 (0.14, 1.16)
1.03 (0.63,1.68)	1.39 (0.85,2.27)	1.31 (0.61,2.79)	1.14 (0.63,2.07)	2.90 (0.66,12.69)	2.54 (0.68,9.53)	10.12 (2.06,49.65)	6.51 (1.77,23.91)	1.24 (0.61,2.55)	0.46 (0.15,1.43)	**educ & mfar(w/med)**			0.93 (0.55, 1.58)
0.47 (0.18,1.21)	0.63 (0.25,1.61)	0.59 (0.20,1.79)	0.52 (0.19,1.42)	1.32 (0.24,7.11)	1.15 (0.24,5.45)	4.59 (0.77,27.46)	2.95 (0.64,13.73)	0.56 (0.19,1.67)	0.21 (0.05,0.85)	0.45 (0.17,1.21)	**cgn & med & ntr & exrc**		1.93 (0.80, 4.69)
0.50 (0.18,1.40)	0.68 (0.25,1.87)	0.64 (0.20,2.06)	0.56 (0.19,1.64)	1.42 (0.25,8.00)	1.24 (0.25,6.15)	4.96 (0.80,30.82)	3.19 (0.66,15.50)	0.61 (0.19,1.93)	0.23 (0.05,0.96)	0.49 (0.17,1.40)	1.08 (0.29,4.08)	**ADL & ntr & exrc**	1.79 (0.68, 4.69)
0.90 (0.66,1.23)	1.22 (0.93,1.59)	1.15 (0.60,2.18)	1.00 (0.63,1.58)	2.55 (0.61,10.60)	2.23 (0.63,7.91)	8.89 (1.90,41.63)	5.71 (1.65,19.83)	1.09 (0.60,2.01)	0.41 (0.14,1.17)	0.88 (0.60,1.29)	1.93 (0.79,4.77)	1.79 (0.67,4.76)	**ac**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR>1 favours the upper left intervention; a OR<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 6 - Intervention rankings for living at home: medium-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & mfar(w/slfm)	95.8	70.5	1.5	1	4
hmcr & mfar	89.1	12.5	2.4	1	5
mfa-(w/med)	72.1	8.7	4.6	1	13
mfa-	69.7	5.7	4.9	1	13
cgn & med & ntr & exrc	66.6	0.6	5.3	2	12
ADL & ntr & exrc	62.5	1.9	5.9	2	13
mfar(w/med)	49.7	0	7.5	5	11
mfar	42.7	0.1	8.4	4	13
educ & rsk-mfa-	39.1	0	8.9	4	13
mfa-(w/med+slfm)	32.5	0	9.8	5	13
ac	31.8	0	9.9	7	12
rsk-mfa-	22.6	0	11.1	7	13
educ & mfar(w/med)	21.9	0	11.2	6	14
educ & mfar(w/med+slfm)	3.9	0	13.5	8	14

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 1 - Pairwise meta-analysis for living at home: medium-term available care network (pooling comparisons with greater than one study reporting results)



Figure 2 - Comparison-adjusted funnel plot for living at home: medium-term available care network

Living at home available care network, long-term timeframe

Table 7 - Long-term living at home available-care network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Carpenter 1990[27]	all	515	rsk-mfa-	ac	-	-	-	+	-	-
Fischer 2009[28]	all	4165	eng & mfa-(w/slfm)	ac	+	-	-	+	+	-
Ford 1971[29]	pre-frail and frail	300	mfar(w/med)	ac	+	-	+	+	+	-
Hay 1998[14]	unclassifiable	486	mfa-	ac	-	-	x	+	-	x
Kerse 2014[17]	pre-frail and frail	3629	rsk-mfa-	ac	+/+	-	-	+	-	-
Kono 2016[19]	pre-frail	302	mfar(w/med)	mfar	+	-	-	+	+	-
Kukkonen-Harjula 2017[3]	pre-frail and frail	299	ADL & ntr & exrc	ac	+	-	+	+	+	-
Metzelthin 2013[5]	frail	315	educ & mfar(w/med+slfm)	ac	-/-	-	x	+	-	x
Stuck 1995[30]	all	414	educ & mfar(w/med)	ac	+	-	+	+	+	-
Stuck 2015[31]	robust and pre-frail	2154	educ & mfar(w/med+slfm)	ac	+	-	x	+	+	x
Suijker 2016[6]	frail	1955	mfar(w/med)	ac	+/-	-	-	+	-	-
Tomita 2007[32]	frail	110	aids	ac	x	-	x	+	-	xx
Tulloch 1979[33]	all	299	mfar(w/med)	ac	-	-	-	+	-	-

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 8 - Results of living at home: long-term available care network

rsk-mfa-									0.91 (0.77, 1.07)
0.77 (0.58,1.02)	**mfar(w/med)**	0.91 (0.46, 1.81)							1.17 (0.94, 1.47)
0.71 (0.34,1.48)	0.91 (0.46,1.81)	**mfar**							
0.43 (0.17,1.09)	0.55 (0.21,1.42)	0.60 (0.19,1.94)	**mfa-**						2.13 (0.85, 5.33)
0.88 (0.68,1.14)	1.14 (0.85,1.54)	1.25 (0.60,2.63)	2.07 (0.81,5.29)	**eng & mfa- (w/slfm)**					1.03 (0.85, 1.25)
0.84 (0.58,1.21)	1.09 (0.73,1.61)	1.19 (0.54,2.61)	1.97 (0.74,5.21)	0.95 (0.65,1.39)	**educ & mfar (w/med+slfm)**				1.02 (0.64, 1.63)
0.74 (0.42,1.30)	0.96 (0.54,1.72)	1.05 (0.43,2.57)	1.74 (0.60,5.03)	0.84 (0.47,1.48)	0.88 (0.47,1.65)	**educ & mfar (w/med)**			1.23 (0.72, 2.10)
0.34 (0.13,0.91)	0.44 (0.17,1.19)	0.49 (0.15,1.61)	0.81 (0.21,3.03)	0.39 (0.15,1.03)	0.41 (0.15,1.12)	0.46 (0.15,1.39)	**aids**		2.64 (1.02, 6.88)
0.79 (0.43,1.44)	1.02 (0.55,1.90)	1.12 (0.45,2.81)	1.85 (0.63,5.48)	0.90 (0.49,1.65)	0.94 (0.49,1.82)	1.07 (0.49,2.35)	2.30 (0.75,7.03)	**ADL & ntr & exrc**	1.15 (0.64, 2.05)
0.91 (0.77,1.07)	1.17 (0.94,1.47)	1.29 (0.63,2.63)	2.13 (0.85,5.33)	1.03 (0.85,1.25)	1.08 (0.78,1.49)	1.23 (0.72,2.10)	2.64 (1.02,6.88)	1.15 (0.64,2.05)	**ac**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR>1 favours the upper left intervention; a OR<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 9 - Intervention rankings for living at home: long-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
aids	91.1	58.3	1.8	1	7
mfa-	83	33.1	2.5	1	9
mfar	55.8	4.8	5	1	10
educ & mfar(w/med)	53.2	2.2	5.2	2	10
mfar(w/med)	53.4	0.3	5.2	3	9
ADL & ntr & exrc	46.5	1.2	5.8	2	10
educ & mfar(w/med+slfm)	41.6	0.1	6.3	3	10
eng & mfa-(w/slfm)	34.9	0	6.9	3	10
ac	27.6	0	7.5	5	9
rsk-mfa-	12.9	0	8.8	6	10

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 3 - Pairwise meta-analysis for living at home: long-term available care network (pooling comparisons with greater than one study reporting results)

Living at home homecare network, short-term timeframe

Table 10 - Short-term living at home homecare network

Study	Frailty	n	Experimental group	Control group	ROB					
					D1	D2	D3	D4	D5	Overall
Fernandez-Barres 2017[34]	frail	163	hmcr & ntr	hmcr	+	-	-	+	-	-
King 2012[35]	pre-frail and frail	174	hmcr & ADL & mfar(w/slfm)	hmcr	+/+	-	+	+	-	-
Parsons M 2017[36]	frail	104	hmcr & ADL & mfar(w/slfm)	hmcr & mfa-	-	-	x	+	+	x
Rooijackers 2021[37]	frail	263	hmcr & ADL & mfar(w/slfm)	hmcr	+/-	-	+	+	-	-

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 11 - Results of living at home: short-term homecare network

hmcr & ntr			0.34 (0.12,0.95)
1.30 (0.29,5.85)	**hmcr & mfa-**	0.41 (0.18,0.95)	
0.54 (0.15,1.88)	0.41 (0.18,0.95)	**hmcr & ADL & mfar(w/slfm)**	0.63 (0.31,1.26)
0.34 (0.12,0.95)	0.26 (0.09,0.77)	0.63 (0.31,1.26)	**hmcr**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR>1 favours the upper left intervention; a OR<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 12 - Intervention rankings for living at home: short-term homecare network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr	95.7	87.4	1.1	1	2
hmcr & ADL & mfar(w/slfm)	64.4	10.4	2.1	1	3
hmcr & ntr	26.2	2.1	3.2	1	4
hmcr & mfa-	13.6	0.1	3.6	3	4

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 4 - Pairwise meta-analysis for living at home: short-term homecare network (pooling comparisons with greater than one study reporting results)

Living at home homecare network, medium-term timeframe

Table 13 - Medium-term living at home homecare network

Study	Frailty	n	Experimental group	Control group	ROB D1	D2	D3	D4	D5	Overall
Fernandez-Barres 2017[34]	frail	156	hmcr & ntr	hmcr	+	-	x	+	-	x
Lewin 2013[38]	frail	744	hmcr & educ & mfar	hmcr	x	x	+	+	-	xx
Parsons M 2017[36]	frail	87	hmcr & ADL & mfar(w/slfm)	hmcr & mfa-	-	-	x	+	+	x
Rooijackers 2021[37]	frail	259	hmcr & ADL & mfar(w/slfm)	hmcr	+/-	-	+	+	-	-
Wolter 2013[39]	frail	732	hmcr & mfar(w/med)	hmcr	+/-	-	x	+	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only).

Table 14 - Results of living at home: medium-term homecare network

hmcr & ntr					0.50 (0.23,1.07)
0.45 (0.20,1.03)	**hmcr & mfar(w/med)**				1.11 (0.82,1.51)
0.98 (0.26,3.67)	2.18 (0.71,6.65)	**hmcr & mfa-**		0.67 (0.28,1.58)	
0.43 (0.19,0.98)	0.95 (0.61,1.47)	0.44 (0.14,1.33)	**hmcr & educ & mfar**		1.17 (0.85,1.59)
0.66 (0.24,1.78)	1.45 (0.71,2.96)	0.67 (0.28,1.58)	1.53 (0.75,3.13)	**hmcr & ADL & mfar(w/slfm)**	0.76 (0.40,1.45)
0.50 (0.23,1.07)	1.11 (0.82,1.51)	0.51 (0.17,1.49)	1.17 (0.85,1.59)	0.76 (0.40,1.45)	**hmcr**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR>1 favours the upper left intervention; a OR<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 15 - Intervention rankings for living at home: medium-term homecare network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & educ & mfar	83.9	50.5	1.8	1	4
hmcr & mfar(w/med)	77.7	33.2	2.1	1	4
hmcr	60.3	3.6	3	1	5
hmcr & ADL & mfar(w/slfm)	43.4	7.9	3.8	1	6
hmcr & mfa-	18.7	3.9	5.1	1	6
hmcr & ntr	16	0.9	5.2	2	6

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.

Living at home homecare care network, long-term timeframe

No results.

IADL available care network, short-term timeframe

Table 16 - Short-term IADL available-care network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Clark 1997[40]	robust and pre-frail	304	eng & educ	ac	x	-	x	-	x	xx
Gitlin 2006[41]	pre-frail and frail	300	ADL & aids & exrc	ac	+	-	x	-	-	x
Metzelthin 2013[5]	frail	316	educ & mfar(w/med+slfm)	ac	-/-	-	x	-	-	x
Morgan 2019[42]	pre-frail	47	exrc	ac	+	-	-	x	-	x
Rockwood 2000[43]	frail	148	mfa-(w/med)	ac	-	-	x	-	-	x
Szanton 2011[7]	pre-frail and frail	40	ADL&aids&educ&exrc& mfar(w/med+slfm)	ac	-	-	x	-	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 17 - Results of IADL: short-term available care network

mfa-(w/med)						-0.05 (-0.37,0.27)
-0.05 (-0.74,0.63)	**exrc**					0.00 (-0.60,0.60)
-0.11 (-0.51,0.29)	-0.06 (-0.71,0.59)	**eng & educ**				0.06 (-0.18,0.30)
0.17 (-0.22,0.56)	0.22 (-0.42,0.87)	0.29 (-0.04,0.61)	**educ & mfar(w/med+slfm)**			-0.22 (-0.45,-0.00)
-0.43 (-1.14,0.29)	-0.38 (-1.25,0.50)	-0.31 (-0.99,0.37)	-0.60 (-1.28,0.08)	**ADL&aids&ed&ex&mf(w/med+slfm)**		0.38 (-0.26,1.01)
-0.19 (-0.58,0.21)	-0.14 (-0.78,0.51)	-0.07 (-0.40,0.25)	-0.36 (-0.68,-0.04)	0.24 (-0.44,0.92)	**ADL & aids & exrc**	0.14 (-0.09,0.36)
-0.05 (-0.37,0.27)	-0.00 (-0.60,0.60)	0.06 (-0.18,0.30)	-0.22 (-0.45,-0.00)	0.38 (-0.26,1.01)	0.14 (-0.09,0.36)	**ac**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 18 - Intervention rankings for IADL: short-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
ADL&aids&ed&ex&mf(w/med+slfm)	85.6	65.7	1.9	1	7
ADL & aids & exrc	70.3	13.2	2.8	1	6
Eng & educ	57.8	4.8	3.5	1	6
Exrc	46.7	13.7	4.2	1	7
available care	44.1	0.1	4.4	3	6
Mfa-(w/med)	36.6	2.4	4.8	1	7
Educ & mfar(w/med+slfm)	8.9	0.1	6.5	5	7

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.

Disconnected Network



Figure 5 - Example of disconnected network for IADL short-term timeframe, showing separation between studies with available care (ac) comparator and homecare (hmcr) comparator

IADL available care network, medium-term timeframe

Table 19 - Medium-term IADL available-care network

Study	Frailty	n	Experimental group	Control group	ROB D1	D2	D3	D4	D5	Overall
Blom 2016[9]	all	1379	mfa-(w/med+slfm)	ac	x/+	-	x	-	-	xx
Bouman 2008[44]	pre-frail and frail	293	mfar(w/med)	ac	+	-	x	-	-	x
Brettschneider 2015[45]	frail	265	mfar(w/med)	ac	-	-	x	-	+	x
Clark 1997[40]	robust and pre-frail	282	eng & educ	ac	x	-	x	-	x	xx
Dorresteijn 2016[46]	unclassifiable	312	ADL	ac	+	-	x	-	-	x
Fabacher 1994[11]	all	195	mfar(w/med)	ac	-	-	x	-	-	x
Gene Huguet 2018[47]	pre-frail	173	med & ntr & exrc	ac	-	-	x	-	-	x
Gitlin 2006[41]	pre-frail and frail	285	ADL & aids & exrc	ac	+	-	x	-	-	x
Henderson 2005[16]	robust	124	mfar	ac	+/x	+	x	+	-	xx
Metzelthin 2013[5]	frail	317	educ & mfar(w/med+slfm)	ac	-/-	-	x	-	-	x
Monteserin Nadal 2008[20]	all	430	educ & rsk-mfa-	ac	-	-	x	-	-	x
Rockwood 2000[43]	frail	145	mfa-(w/med)	ac	-	-	x	-	-	x
Rubenstein 2007[48]	frail	694	mfar(w/med)	ac	-	-	-	-	-	-
Szanton 2019[49]	pre-frail and frail	260	ADL&aids&educ&exrc& mfar(w/med+slfm)	ac	+	-	x	-	-	x
Tomita 2007[32]	frail	78	aids	ac	x	-	x	-	-	xx
van Heuvelen 2005[50]	pre-frail and frail	77	exrc & psyc	ac	-	x	x	-	-	xx

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 20 - Results of IADL: medium-term available care network

mfar(w/med)													0.11 (-0.00, 0.22)
-0.40 (-0.77,-0.03)	**mfar**												0.50 (0.15, 0.86)
0.18 (0.01,0.35)	0.58 (0.20,0.96)	**mfa-(w/med+slfm)**											-0.07 (-0.20, 0.06)
0.08 (-0.26,0.42)	0.48 (-0.00,0.96)	-0.10 (-0.45,0.25)	**mfa-(w/med)**										0.02 (-0.30, 0.35)
-0.11 (-0.42,0.21)	0.29 (-0.18,0.76)	-0.29 (-0.61,0.04)	-0.19 (-0.63,0.25)	**med & ntr & exrc**									0.21 (-0.08, 0.51)
0.22 (-0.28,0.72)	0.62 (0.01,1.23)	0.04 (-0.46,0.55)	0.14 (-0.45,0.73)	0.33 (-0.24,0.90)	**exrc & psyc**								-0.12 (-0.60, 0.37)
0.12 (-0.15,0.39)	0.52 (0.08,0.95)	-0.06 (-0.34,0.22)	0.04 (-0.37,0.44)	0.23 (-0.16,0.61)	-0.10 (-0.65,0.44)	**eng & educ**							-0.01 (-0.26, 0.23)
0.11 (-0.11,0.32)	0.50 (0.10,0.91)	-0.07 (-0.30,0.16)	0.02 (-0.35,0.40)	0.21 (-0.14,0.57)	-0.12 (-0.64,0.41)	-0.01 (-0.32,0.30)	**educ & rsk-mfa-**						0.00 (-0.19, 0.19)
0.24 (-0.01,0.48)	0.63 (0.21,1.06)	0.06 (-0.20,0.31)	0.15 (-0.24,0.55)	0.34 (-0.03,0.72)	0.01 (-0.52,0.55)	0.12 (-0.21,0.45)	0.13 (-0.16,0.42)	**educ & mfar(w/med+slfm)**					-0.13 (-0.35, 0.09)
0.26 (-0.20,0.72)	0.65 (0.08,1.23)	0.07 (-0.39,0.54)	0.17 (-0.38,0.73)	0.36 (-0.18,0.90)	0.03 (-0.63,0.70)	0.14 (-0.37,0.65)	0.15 (-0.34,0.64)	0.02 (-0.48,0.52)	**aids**				-0.15 (-0.60, 0.30)
0.67 (0.40,0.94)	1.07 (0.63,1.50)	0.49 (0.21,0.77)	0.59 (0.18,1.00)	0.78 (0.39,1.16)	0.45 (-0.10,0.99)	0.55 (0.20,0.90)	0.56 (0.25,0.87)	0.43 (0.10,0.76)	0.41 (-0.10,0.92)	**ADL&aids&ed&ex&mf(w/med+slfm)**			-0.56 (-0.81, -0.31)
0.30 (0.04,0.55)	0.70 (0.27,1.12)	0.12 (-0.15,0.38)	0.22 (-0.18,0.62)	0.41 (0.03,0.79)	0.08 (-0.47,0.62)	0.18 (-0.16,0.52)	0.19 (-0.11,0.49)	0.06 (-0.26,0.38)	0.04 (-0.46,0.55)	-0.37 (-0.71,-0.03)	**ADL & aids & exrc**		-0.19 (-0.42, 0.04)
0.00 (-0.24,0.25)	0.40 (-0.02,0.82)	-0.18 (-0.44,0.08)	-0.08 (-0.48,0.31)	0.11 (-0.26,0.48)	-0.22 (-0.76,0.32)	-0.12 (-0.45,0.22)	-0.10 (-0.40,0.19)	-0.24 (-0.55,0.08)	-0.25 (-0.75,0.25)	-0.67 (-1.00,-0.33)	-0.30 (-0.62,0.03)	**ADL**	0.10 (-0.12, 0.33)
0.11 (0.00,0.21)	0.50 (0.15,0.86)	-0.07 (-0.20,0.06)	0.02 (-0.30,0.35)	0.21 (-0.08,0.51)	-0.12 (-0.60,0.37)	-0.01 (-0.26,0.23)	0.00 (-0.19,0.19)	-0.13 (-0.35,0.09)	-0.15 (-0.60,0.30)	-0.56 (-0.81,-0.31)	-0.19 (-0.42,0.04)	0.10 (-0.12,0.33)	**ac**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 21 - Intervention rankings for IADL: medium-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
mfar	98.3	86.3	1.2	1	4
Med & ntr & exrc	83.1	8.7	3.2	1	10
Mfar(w/med)	73.9	0.6	4.4	2	7
ADL	70.2	1.1	4.9	2	10
Mfa-(w/med)	55.9	1.1	6.7	2	13
Educ & rsk-mfa-	52.7	0.2	7.1	3	12
ac	52.4	0	7.2	5	9
Eng & educ	50.3	0.2	7.5	2	13
Exrc & psyc	38.9	1.1	8.9	2	14
Mfa-(w/med+slfm)	37.3	0	9.2	5	12
aids	33.9	0.7	9.6	2	14
Educ & mfar(w/med+slfm)	30.4	0	10.1	5	13
ADL & aids & exrc	21.8	0	11.2	5	13
ADl&aids&ed&ex&mf(w/med+slfm)	0.9	0	13.9	13	14

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 6 - Pairwise meta-analysis for IADL: medium-term available care network (pooling comparisons with greater than one study reporting results)



Figure 7 - Comparison-adjusted funnel plot for IADL: medium-term available care network



Figure 8 - Example of disconnected network for IADL medium-term timeframe, showing separation between studies with available care (ac) comparator and homecare (hmcr) comparator



Figure 9 - Rankogram showing comparative effectiveness of interventions for IADL medium-term available care network. Results based on a simulation of 1000 replications.

Risk of Bias



Figure 10 - Example of disconnected network for risk of bias sensitivity analysis for IADL medium-term timeframe, showing separation between studies with available care (ac) comparator and homecare (hmcr) comparator



Figure 11 – Network diagram for risk of bias analysis for IADL medium-term timeframe with available care (ac) comparator

IADL available care network, long-term timeframe

Table 22 - Long-term IADL available-care network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Bouman 2008[44]	pre-frail and frail	293	mfar(w/med)	ac	+	-	x	-	-	x
Jitapunkul 1998[51]	unclassifiable	116	rsk-mfa-	ac	-	-	-	-	-	-
Metzelthin 2013[5]	frail	316	educ & mfar(w/med+slfm)	ac	-/-	-	x	-	-	x
Rubenstein 2007[48]	frail	607	mfar(w/med)	ac	-	-	-	-	-	-
Stuck 1995[30]	all	317	educ & mfar(w/med)	ac	+	-	-	-	-	-
Tomita 2007[32]	frail	78	aids	ac	x	-	x	-	-	xx

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 23 - Results of IADL: long-term available care network

rsk-mfa-					0.23 (-0.13,0.60)
0.32 (-0.07,0.70)	**mfar(w/med)**				-0.08 (-0.21,0.05)
0.45 (0.02,0.87)	0.13 (-0.13,0.39)	**educ & mfar(w/med+slfm)**			-0.21 (-0.44,0.01)
0.09 (-0.33,0.52)	-0.22 (-0.48,0.03)	-0.35 (-0.67,-0.04)	**educ & mfar(w/med)**		0.14 (-0.08,0.36)
0.26 (-0.32,0.84)	-0.05 (-0.52,0.41)	-0.19 (-0.69,0.31)	0.17 (-0.33,0.67)	**aids**	-0.03 (-0.48,0.42)
0.23 (-0.13,0.60)	-0.08 (-0.21,0.05)	-0.21 (-0.44,0.01)	0.14 (-0.08,0.36)	-0.03 (-0.48,0.42)	**ac**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 24 - Intervention rankings for IADL: long-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
rsk-mfa-	86.5	61.9	1.7	1	5
educ & mfar(w/med)	77.3	25.5	2.1	1	5
ac	52.5	0.4	3.4	2	5
aids	44.3	11.9	3.8	1	6
mfar(w/med)	29.7	0.1	4.5	3	6
educ & mfar(w/med+slfm)	9.7	0.2	5.5	4	6

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 12 - Pairwise meta-analysis for IADL: long-term available care network (pooling comparisons with greater than one study reporting results)



Figure 13 - Example of disconnected network for IADL long-term timeframe, showing separation between studies with available care (ac) comparator and homecare (hmcr) comparator



Figure 14 - Rankogram showing comparative effectiveness of interventions for IADL long-term available care network. Results based on a simulation of 1000 replications.

IADL homecare network, short-term timeframe

Table 25 - Short-term IADL homecare network

Study	Frailty	n	Experimental group	Control group	ROB					
					D1	D2	D3	D4	D5	Overall
Auvinen 2020[52]	frail	449	hmcr & med	hmcr	+	-	-	-	x	x
King 2012[35]	pre-frail and frail	157	hmcr & ADL & mfar(w/slfm)	hmcr	+/+	-	-	-	-	-
Parsons M 2012[53]	frail	251	hmcr & mfar	hmcr & mfa-	+/-	-	-	-	-	-
Parsons M 2017[36]	frail	113	hmcr & ADL & mfar(w/slfm)	hmcr & mfa-	-	-	x	-	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 26 - Results of IADL: short-term homecare network

hmcr & mfar	0.10 (-0.14,0.35)			
0.10 (-0.14,0.35)	**hmcr & mfa-**		-0.05 (-0.41,0.32)	
0.16 (-0.41,0.74)	0.06 (-0.46,0.58)	**hmcr & med**		-0.13 (-0.31,0.06)
0.06 (-0.39,0.50)	-0.05 (-0.41,0.32)	-0.11 (-0.47,0.26)	**hmcr & ADL & mfar(w/slfm)**	-0.02 (-0.33,0.29)
0.04 (-0.51,0.58)	-0.07 (-0.55,0.42)	-0.13 (-0.31,0.06)	-0.02 (-0.33,0.29)	**hmcr**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 27 - Intervention rankings for IADL: short-term homecare network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & mfar	64.7	41.5	2.4	1	5
hmcr	62.8	30.4	2.5	1	5
hmcr & ADL & mfar(w/s)	54.5	17.1	2.8	1	5
hmcr & mfa-	39.2	6.4	3.4	1	5
hmcr & med	28.7	4.6	3.9	1	5

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.

IADL homecare network, medium-term timeframe

Table 28 - Medium-term IADL homecare network

Study	Frailty	n	Experimental group	Control group	ROB D1	D2	D3	D4	D5	Overall
Bernabei 1998[54]	frail	199	hmcr & mfar(w/med)	hmcr	-	-	x	-	-	x
Mann WC 1999[55]	frail	90	hmcr & aids	hmcr	-	-	x	+	-	x
Parsons M 2012[53]	frail	251	hmcr & mfar	hmcr & mfa-	+/-	-	x	-	-	x
Parsons M 2017[36]	frail	113	hmcr & ADL & mfar(w/slfm)	hmcr & mfa-	-	-	x	-	-	xx
Rooijackers 2021[37]	frail	264	hmcr & ADL & mfar(w/slfm)	hmcr	+/-	-	x	+	x	xx
Wolter 2013[39]	frail	484	hmcr & mfar(w/med)	hmcr	+/-	-	x	+	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 29 - Results of IADL: medium-term homecare network

hmcr & mfar(w/med)					0.15 (-0.11,0.40)
-0.03 (-0.78,0.71)	**hmcr & mfar**	0.19 (-0.06,0.44)			
0.16 (-0.49,0.80)	0.19 (-0.18,0.56)	**hmcr & mfa-**		-0.17 (-0.54,0.20)	
-0.13 (-0.69,0.44)	-0.09 (-0.95,0.76)	-0.28 (-1.05,0.49)	**hmcr & aids**		0.27 (-0.14,0.69)
-0.01 (-0.46,0.44)	0.02 (-0.57,0.61)	-0.17 (-0.63,0.29)	0.11 (-0.51,0.73)	**hmcr & ADL & mfar(w/slfm)**	0.16 (-0.08,0.40)
0.15 (-0.11,0.41)	0.18 (-0.52,0.88)	-0.01 (-0.60,0.58)	0.27 (-0.23,0.77)	0.16 (-0.21,0.53)	**hmcr**

Table 30 - Intervention rankings for IADL: medium-term homecare network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & aids	69	41.2	2.6	1	6
hmcr & mfar	61.1	31.5	2.9	1	6
hmcr & ADL & mfar(w/slfm)	58.5	11.7	3.1	1	6
hmcr & mfar(w/med)	55.5	13.1	3.2	1	6
hcmr & mfa-	30.2	2.2	4.5	2	6
hmcr	25.7	0.3	4.7	2	6

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 15 - Pairwise meta-analysis for IADL: medium-term homecare network (pooling comparisons with greater than one study reporting results)



Figure 16 - Rankogram showing comparative effectiveness of interventions for IADL medium-term homecare network. Results based on a simulation of 1000 replications.

PADL available care network, short-term timeframe

Table 31 - Short-term PADL available-care network

Study	Frailty	n	Experimental group	Control group	ROB					
					D1	D2	D3	D4	D5	Overall
Bleijenberg 2016[56]	pre-frail and frail	2754	rsk-mfa-	ac	x/+	-	x	+	-	xx
Clark 1997[40]	robust and pre-frail	303	eng & educ	ac	x	-	x	-	x	xx
Gitlin 2006[41]	pre-frail and frail	300	ADL & aids & exrc	ac	+	-	x	-	-	x
Metzelthin 2013[5]	frail	316	educ & mfar(w/med+slfm)	ac	-/-	-	x	-	-	x
Rockwood 2000[43]	frail	148	mfa-(w/med)	ac	-	-	x	-	-	x
Szanton 2011[7]	pre-frail and frail	40	ADL&aids&educ&exrc& mfar(w/med+slfm)	ac	-	-	x	-	-	x
Takahashi 2012[57]	frail	166	mntr-mfa-	ac	-	-	x	-	-	x
Walters 2017[58]	pre-frail	48	mfar(w/slfm)	ac	+	-	x	-	x	xx

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 32 - Results of PADL: short-term available care network

rsk-mfa-								0.03 (-0.06,0.11)
0.12 (-0.20,0.43)	**mntr-mfa-**							-0.09 (-0.40,0.21)
-0.65 (-1.24,-0.06)	-0.77 (-1.42,-0.11)	**mfar(w/slfm)**						0.67 (0.09,1.26)
0.14 (-0.19,0.47)	0.02 (-0.42,0.47)	0.79 (0.12,1.45)	**mfa-(w/med)**					-0.11 (-0.44,0.21)
0.03 (-0.23,0.28)	-0.09 (-0.48,0.29)	0.67 (0.04,1.30)	-0.11 (-0.52,0.29)	**eng & educ**				0.00 (-0.24,0.24)
0.27 (0.04,0.51)	0.15 (-0.22,0.53)	0.92 (0.30,1.55)	0.13 (-0.26,0.53)	0.25 (-0.08,0.57)	**educ & mfar(w/med+slfm)**			-0.25 (-0.47,-0.03)
-0.84 (-1.51,-0.17)	-0.96 (-1.69,-0.23)	-0.20 (-1.08,0.69)	-0.98 (-1.72,-0.24)	-0.87 (-1.58,-0.16)	-1.12 (-1.82,-0.42)	**ADL&aids&ed&ex&mf(w/med+slfm)**		0.87 (0.20,1.53)
-0.11 (-0.35,0.13)	-0.23 (-0.61,0.15)	0.54 (-0.09,1.16)	-0.25 (-0.64,0.14)	-0.14 (-0.47,0.19)	-0.38 (-0.70,-0.07)	0.73 (0.03,1.43)	**ADL & aids & exrc**	0.14 (-0.09,0.36)
0.03 (-0.06,0.11)	-0.09 (-0.40,0.21)	0.67 (0.09,1.26)	-0.11 (-0.44,0.21)	0.00 (-0.24,0.24)	-0.25 (-0.47,-0.03)	0.87 (0.20,1.53)	0.14 (-0.09,0.36)	**ac**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 33 - Intervention rankings for PADL: short-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
ADL&aids&ed&ex&mf(w/med+slfm)	95.1	67.2	1.4	1	2
mfar(w/slfm)	89.8	32.3	1.8	1	4
ADL & aids & exrc	66.3	0.3	3.7	2	7
rsk-mfa-	50.8	0	4.9	3	7
eng & educ	44	0.1	5.5	3	9
ac	42.5	0	5.6	4	8
mntr-mfa-	28.3	0	6.7	3	9
mfa-(w/med)	25.6	0.1	7	3	9
educ & mfar(w/med+slfm)	7.5	0	8.4	6	9

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 17 - Rankogram showing comparative effectiveness of interventions for PADL short-term available care network. Results based on a simulation of 1000 replications.

PADL available care network, medium-term timeframe

Table 34 - Medium-term PADL available-care network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Bleijenberg 2016[56]	pre-frail and frail	2489	rsk-mfa-	ac	x/+	-	x	+	-	xx
Blom 2016[9]	all	1379	mfa-(w/med+slfm)	ac	x/+	-	x	-	-	xx
Bouman 2008[44]	pre-frail and frail	293	mfar(w/med)	ac	+	-	x	-	-	x
Brettschneider 2015[45]	frail	262	mfar(w/med)	ac	-	-	x	-	+	x
Cameron 2013[59]	frail	214	exrc & mfar(w/med+slfm)	ac	+	-	-	-	+	-
Clark 1997[40]	robust and pre-frail	281	eng & educ	ac	x	-	x	-	x	xx
Dorresteijn 2016[46]	unclassifiable	312	ADL	ac	+	-	x	-	-	x
Fabacher 1994[11]	all	195	mfar(w/med)	ac	-	-	x	-	-	x
Gene Huguet 2018[47]	pre-frail	173	med & ntr & exrc	ac	-	-	x	-	-	x
Henderson 2005[16]	robust	124	mfar	ac	+/x	+	x	+	-	xx
Kono 2016[19]	pre-frail	360	mfar(w/med)	mfar	+	-	x	-	-	x
Metzelthin 2013[5]	frail	317	educ & mfar(w/med+slfm)	ac	-/-	-	x	-	-	x
Monteserin Nadal 2008[20]	all	620	educ & rsk-mfa-	ac	-	-	x	x	-	xx
Newbury 2001[21]	unclassifiable	89	mfa-(w/med)	ac	-	-	x	-	-	x
Rockwood 2000[43]	frail	145	mfa-(w/med)	ac	-	-	x	-	-	x
Rubenstein 2007[48]	frail	694	mfar(w/med)	ac	-	-	-	-	-	-
Serra-Prat 2017[60]	pre-frail	133	ntr & exrc	ac	-	-	x	-	-	x
Szanton 2019[49]	pre-frail and frail	260	ADL&aids&educ&exrc& mfar(w/med+slfm)	ac	+	-	x	-	-	x
Takahashi 2012[57]	frail	166	mntr-mfa-	ac	-	-	x	-	-	x
van Heuvelen 2005[50]	pre-frail and frail	77	exrc & psyc	ac	-	x	x	-	-	xx

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 35 - Results of PADL: medium-term available care network

rsk-mfa-															0.13 (0.04, 0.22)
0.13 (-0.80,1.06)	**ntr & exrc**														0.00 (-0.34, 0.34)
0.30 (-0.61,1.22)	0.17 (-0.80,1.15)	**mntr-mfa-**													-0.17 (-0.48, 0.13)
0.08 (-0.60,0.77)	-0.05 (-0.81,0.71)	-0.22 (-0.97,0.53)	**mfar(w/med)**	0.03 (-0.18, 0.24)											0.11 (0.00, 0.21)
0.27 (-0.52,1.07)	0.14 (-0.72,1.00)	-0.03 (-0.88,0.81)	0.19 (-0.31,0.68)	**mfar**											-0.33 (-0.69, 0.02)
0.17 (-0.70,1.04)	0.04 (-0.89,0.97)	-0.13 (-1.05,0.79)	0.09 (-0.61,0.78)	-0.10 (-0.90,0.70)	**mfa-(w/med+slfm)**										-0.04 (-0.17, 0.09)
-0.38 (-1.18,0.42)	-0.51 (-1.37,0.36)	-0.68 (-1.53,0.17)	-0.46 (-1.06,0.14)	-0.65 (-1.37,0.07)	-0.55 (-1.35,0.26)	**mfa-(w/med)**									0.55 (-0.59, 1.70)
-0.18 (-1.10,0.73)	-0.31 (-1.29,0.66)	-0.49 (-1.45,0.47)	-0.27 (-1.01,0.48)	-0.46 (-1.30,0.39)	-0.35 (-1.27,0.57)	0.20 (-0.65,1.05)	**med & ntr & exrc**								0.31 (0.01, 0.61)
0.13 (-0.86,1.12)	-0.00 (-1.05,1.05)	-0.17 (-1.21,0.86)	0.05 (-0.79,0.89)	-0.14 (-1.07,0.79)	-0.04 (-1.04,0.96)	0.51 (-0.42,1.44)	0.31 (-0.72,1.35)	**exrc & psyc**							0.00 (-0.49, 0.49)
-0.03 (-0.93,0.88)	-0.16 (-1.12,0.80)	-0.33 (-1.28,0.62)	-0.11 (-0.84,0.62)	-0.30 (-1.13,0.53)	-0.20 (-1.11,0.71)	0.35 (-0.49,1.19)	0.16 (-0.79,1.10)	-0.16 (-1.18,0.87)	**exrc & mfar(w/med+slfm)**						0.16 (-0.11, 0.43)
0.18 (-0.72,1.08)	0.05 (-0.91,1.00)	-0.13 (-1.07,0.82)	0.10 (-0.63,0.82)	-0.09 (-0.92,0.73)	0.01 (-0.90,0.91)	0.56 (-0.28,1.39)	0.36 (-0.58,1.30)	0.05 (-0.97,1.07)	0.21 (-0.73,1.14)	**eng & educ**					-0.05 (-0.30, 0.20)
0.16 (-0.72,1.04)	0.03 (-0.91,0.97)	-0.14 (-1.07,0.78)	0.08 (-0.62,0.78)	-0.11 (-0.91,0.69)	-0.01 (-0.89,0.88)	0.54 (-0.27,1.35)	0.35 (-0.58,1.27)	0.03 (-0.97,1.03)	0.19 (-0.72,1.10)	-0.02 (-0.92,0.89)	**educ & rsk-mfa-**				-0.03 (-0.19, 0.13)
0.40 (-0.49,1.29)	0.27 (-0.68,1.22)	0.09 (-0.84,1.03)	0.31 (-0.40,1.03)	0.13 (-0.69,0.94)	0.23 (-0.67,1.12)	0.78 (-0.05,1.60)	0.58 (-0.36,1.52)	0.27 (-0.75,1.28)	0.43 (-0.50,1.35)	0.22 (-0.70,1.14)	0.24 (-0.67,1.14)	**educ & mfar(w/med+slfm)**			-0.27 (-0.49, -0.05)
0.06 (-0.84,0.96)	-0.07 (-1.03,0.89)	-0.24 (-1.19,0.70)	-0.02 (-0.75,0.70)	-0.21 (-1.04,0.61)	-0.11 (-1.01,0.79)	0.44 (-0.39,1.27)	0.24 (-0.70,1.19)	-0.07 (-1.09,0.95)	0.09 (-0.84,1.02)	-0.12 (-1.04,0.81)	-0.10 (-1.01,0.80)	-0.34 (-1.26,0.58)	**ADL&aids&ed&ex&mf(w/med+slfm)**		0.07 (-0.17, 0.31)
-0.09 (-0.99,0.80)	-0.22 (-1.18,0.73)	-0.40 (-1.34,0.54)	-0.18 (-0.89,0.54)	-0.37 (-1.19,0.45)	-0.26 (-1.16,0.63)	0.28 (-0.54,1.11)	0.09 (-0.85,1.03)	-0.22 (-1.24,0.79)	-0.07 (-0.99,0.86)	-0.27 (-1.19,0.65)	-0.26 (-1.16,0.65)	-0.49 (-1.41,0.42)	-0.15 (-1.08,0.77)	**ADL**	0.22 (0.00, 0.45)
0.13 (-0.48,0.74)	0.00 (-0.70,0.70)	-0.17 (-0.85,0.51)	0.05 (-0.26,0.35)	-0.14 (-0.65,0.36)	-0.04 (-0.66,0.58)	0.51 (-0.01,1.02)	0.31 (-0.36,0.99)	0.00 (-0.78,0.78)	0.16 (-0.51,0.82)	-0.05 (-0.70,0.61)	-0.03 (-0.66,0.60)	-0.27 (-0.91,0.38)	0.07 (-0.58,0.72)	0.22 (-0.42,0.87)	**ac**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 36 - Intervention rankings for PADL: medium-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
mfa-(w/med)	87.6	34.3	2.9	1	10
med & ntr & exrc	71.5	18.4	5.3	1	15
ADL	64.8	11	6.3	1	15
exrc & mfar(w/med+slfm)	62.5	9.7	6.6	1	16
rsk-mfa-	57.6	6.1	7.4	1	16
ADL&aids&ed&ex&mf(w/med+slfm)	52.4	4.2	8.1	1	16
mfar(w/med)	50.8	0.1	8.4	3	14
exrc & psyc	46.4	5.3	9	1	16
ntr & exrc	45.9	3.8	9.1	1	16
ac	45.1	0	9.2	6	12
mfa-(w/med+slfm)	43	1.9	9.5	2	16
educ & rsk-mfa-	42.9	1.5	9.6	2	16
eng & educ	39.4	1.7	10.1	2	16
mntr-mfa-	34.2	1	10.9	3	16
mfar	32.2	0.2	11.2	3	16
educ & mfar(w/med+slfm)	23.6	0.8	12.5	3	16

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 18 - Rankogram showing comparative effectiveness of interventions for PADL medium-term available care network. Results based on a simulation of 1000 replications.



Figure 19 - Pairwise meta-analysis for PADL: medium-term available care network (pooling comparisons with greater than one study reporting results)



Figure 20 - Comparison-adjusted funnel plot for PADL medium-term timeframe



Figure 21 - Network plot for risk of bias analysis for PADL medium-term timeframe with available care (ac) comparator



Figure 22 - Rankogram showing comparative effectiveness of interventions for risk of bias sensitivity analysis for PADL medium-term available care network. Results based on a simulation of 1000 replications.

PADL available care network, long-term timeframe

Table 37 - Long-term PADL available-care network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Balaban 1988[61]	frail	86	mfa-(w/med)	ac	x	x	x	-	-	xx
Bouman 2008[44]	pre-frail and frail	293	mfar(w/med)	ac	+	-	x	-	-	x
Jitapunkul 1998[51]	unclassifiable	116	rsk-mfa-	ac	-	-	-	-	-	-
Kono 2016[19]	pre-frail	360	mfar(w/med)	mfar	+	-	x	-	-	x
Metzelthin 2013[5]	frail	316	educ & mfar(w/med+slfm)	ac	-/-	-	x	-	-	x
Rubenstein 2007[48]	frail	607	mfar(w/med)	ac	-	-	-	-	-	-
Stuck 1995[30]	all	317	educ & mfar(w/med)	ac	+	-	-	-	-	-

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 38 - Results of PADL: long-term available care network

rsk-mfa-						0.06 (-0.30, 0.43)
0.09 (-0.30,0.48)	**mfar(w/med)**	0.35 (0.14, 0.56)				-0.03 (-0.16, 0.10)
0.44 (-0.00,0.88)	0.35 (0.14,0.56)	**mfar**				
0.23 (-0.32,0.79)	0.15 (-0.30,0.59)	-0.20 (-0.69,0.29)	**mfa-(w/med)**			-0.17 (-0.60, 0.25)
0.34 (-0.09,0.76)	0.25 (-0.01,0.50)	-0.10 (-0.43,0.23)	0.10 (-0.38,0.58)	**educ & mfar(w/med+slfm)**		-0.27 (-0.50, -0.05)
-0.05 (-0.47,0.38)	-0.14 (-0.39,0.12)	-0.48 (-0.81,-0.15)	-0.28 (-0.76,0.20)	-0.38 (-0.69,-0.07)	**educ & mfar(w/med)**	0.11 (-0.11, 0.33)
0.06 (-0.30,0.43)	-0.03 (-0.16,0.10)	-0.37 (-0.62,-0.13)	-0.17 (-0.60,0.25)	-0.27 (-0.50,-0.05)	0.11 (-0.11,0.33)	**AC**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 39 - Intervention rankings for PADL: long-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
educ & mfar(w/med)	85.4	46.2	1.9	1	5
rsk-mfa-	74.8	38.7	2.5	1	6
ac	65.9	3.4	3.0	1	5
mfar(w/med)	58.9	4.5	3.5	1	5
mfa-(w/med)	36.8	7.2	4.8	1	7
educ & mfar(w/med+slfm)	20.1	0	5.8	4	7
mfar	8.2	0	6.5	5	7

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 23 - Pairwise meta-analysis for PADL: long-term available care network (pooling comparisons with greater than one study reporting results)

Figure 24 - Rankogram showing comparative effectiveness of interventions for PADL long-term available care network. Results based on a simulation of 1000 replications.

PADL homecare network, short-term timeframe

Table 40 - Short-term PADL homecare network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Auvinen 2020[52]	frail	449	hmcr & med	hmcr	+	-	-	-	x	x
Fernandez-Barres 2017[34]	frail	111	hmcr & ntr	hmcr	+	-	x	-	-	x
King 2012[35]	pre-frail and frail	157	hmcr & ADL & mfar(w/slfm)	hmcr	+/+	-	-	-	-	-
Teut 2013[62]	frail	58	hmcr & hmnt & exrc	hmcr	+/+	-	x	-	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 41 - Results of PADL: short-term homecare network

hmcr & ntr				0.13 (-0.24,0.51)
0.18 (-0.24,0.60)	**hmcr & med**			-0.05 (-0.23,0.14)
0.10 (-0.54,0.74)	-0.08 (-0.63,0.47)	**hmcr & hmnt & exrc**		0.03 (-0.48,0.55)
0.02 (-0.47,0.51)	-0.16 (-0.52,0.20)	-0.08 (-0.68,0.52)	**hmcr & ADL & mfar(w/slfm)**	0.11 (-0.20,0.43)
0.13 (-0.24,0.51)	-0.05 (-0.23,0.14)	0.03 (-0.48,0.55)	0.11 (-0.20,0.43)	**hmcr**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 42 - Intervention rankings for PADL: short-term homecare network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & ntr	66.7	37.9	2.3	1	5
hmcr & ADL & mfar(w/slfm)	66	29.2	2.4	1	5
hmcr & hmnt & exrc	50.1	28.5	3	1	5
hmcr	40.4	1.8	3.4	2	5
hmcr & med	26.8	2.6	3.9	2	5

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.

Intervention group ranking plots



Figure 25 - Rankogram showing comparative effectiveness of interventions for PADL short-term homecare network. Results based on a simulation of 1000 replications.

PADL homecare network, medium-term timeframe

Table 43 - Medium-term PADL homecare network

Study	Frailty	n	Experimental group	Control group	ROB D1	D2	D3	D4	D5	Overall
Bernabei 1998[54]	frail	199	hmcr & mfar(w/med)	hmcr	-	-	x	-	-	x
Fernandez-Barres 2017[34]	frail	111	hmcr & ntr	hmcr	+	-	x	-	-	x
Rooijackers 2021[37]	frail	264	hmcr & ADL & mfar(w/slfm)	hmcr	+/-	-	x	+	x	xx
Teut 2013[62]	frail	58	hmcr & hmnt & exrc	hmcr	+/+	-	x	-	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 44 - Results of PADL: medium-term homecare network

hmcr & ntr				0.23 (-0.15,0.60)
-0.37 (-0.84,0.10)	**hmcr & mfar(w/med)**			0.60 (0.31,0.88)
0.13 (-0.51,0.77)	0.50 (-0.08,1.09)	**hmcr & hmnt & exrc**		0.10 (-0.42,0.61)
0.11 (-0.34,0.56)	0.48 (0.11,0.86)	-0.02 (-0.59,0.55)	**hmcr & ADL & mfar(w/slfm)**	0.12 (-0.13,0.36)
0.23 (-0.15,0.60)	0.60 (0.31,0.88)	0.10 (-0.42,0.61)	0.12 (-0.13,0.36)	**hmcr**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 45 - Intervention rankings for PADL: medium-term homecare network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & mfar(w/med)	97	89	1.1	1	2
hmcr & ntr	57.5	5.9	2.7	1	5
hmcr & ADL & mfar(w/slfm)	41.2	0.3	3.4	2	5
hmcr & hmnt & exrc	39	4.8	3.4	1	5
hmcr	15.3	0	4.4	3	5

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 26 - Rankogram showing comparative effectiveness of interventions for PADL medium-term homecare network. Results based on a simulation of 1000 replications.



Figure 27 - Network plot for risk of bias analysis for PADL medium-term homecare network

Table 46 - Intervention rankings for risk of bias analysis for PADL: medium-term homecare network

Intervention group	SUCRA	PrBest	Mean Rank	95% CI for true rank
hmcr & mfar(w/med)	96.1	89.4	1.1	1 - 2
hmcr & ntr	53.1	5.6	2.4	1 - 4
hmcr & hmnt & exrc	35.2	5	2.9	1 - 4
hmcr	15.6	0	3.5	2 - 4



Figure 28 - Rankogram showing comparative effectiveness of interventions for risk of bias sensitivity analysis for PADL medium-term homecare network. Results based on a simulation of 1000 replications.

Table 47 - Results of risk of bias PADL: medium-term homecare network

hmcr	-0.23 (-0.60,0.15)	**-0.60 (-0.88,-0.32)**	-0.10 (-0.61,0.42)
-0.23 (-0.60,0.15)	**hmcr & ntr**		
-0.60 (-0.88,-0.32)	-0.37 (-0.84,0.10)	**hmcr & mfar(w/med)**	
-0.10 (-0.61,0.42)	0.13 (-0.51,0.77)	0.50 (-0.08,1.09)	**hmcr & hmnt & exrc**

Hospitalisation (available care network, medium-term timeframe only)

Table 48 - Medium-term hospitalisation available-care network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Bouman 2008[44]	pre-frail and frail	330	mfar(w/med)	ac	+	-	+	+	-	-
Cameron 2013[59]	frail	241	exrc & mfar(w/med+slfm)	ac	+	-	+	+	+	-
Harari 2008[13]	all	1969	mfar(w/med)	ac	+	x	x	+	+	xx
Henderson 2005[16]	robust	124	mfar	ac	+/x	+	x	+	-	xx
Hendriksen 1984[63]	all	543	mfar	ac	-	-	x	+	-	x
Kono 2016[19]	pre-frail	305	mfar(w/med)	mfar	+	-	x	+	-	x
Leveille 1998[64]	unclassifiable	200	educ & exrc & mfar(w/med+slfm)	ac	+	-	+	+	-	-
Newcomer 2004[22]	unclassifiable	3055	educ & mfar(w/med)	ac	-	-	-	+	-	-
Ng 2015[65]	pre-frail and frail	92	cgn & ntr & exrc	ac	+	-	x	+	-	x
Phelan 2007[66]	all	299	mfar(w/med+slfm)	ac	-/x	-	x	+	-	xx
Rubenstein 2007[48]	frail	694	mfar(w/med)	ac	-	-	x	+	-	x
Takahashi 2012[57]	frail	205	mntr-mfa-	ac	-	-	x	+	+	x
van Hout 2010[26]	frail	651	mfar(w/med)	ac	+	-	-	+	-	-
van Lieshout 2018[67]	pre-frail and frail	281	ADL & med & ntr & sst	ac	-	-	x	+	-	xx
van Rossum 1993[68]	all	580	mfar	ac	-	-	-	+	-	-

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 49 - Results of hospitalisation medium-term analysis

mntr-mfa-									1.39 (0.80, 2.42)
1.01 (0.45, 2.29)	**mfar(w/med+ slfm)**								1.38 (0.76, 2.50)
1.26 (0.71, 2.23)	1.25 (0.67, 2.31)	**mfar(w/med)**	1.07 (0.59, 1.97)						1.12 (0.96, 1.30)
1.72 (0.93, 3.19)	1.70 (0.88, 3.29)	1.36 (1.01, 1.83)	**mfar**						0.76 (0.56, 1.03)
1.04 (0.49, 2.21)	1.03 (0.47, 2.26)	0.82 (0.48, 1.40)	0.60 (0.34, 1.08)	**exrc & mfar(w/med+ slfm)**					1.34 (0.80, 2.24)
1.51 (0.85, 2.69)	1.49 (0.80, 2.78)	1.20 (0.96, 1.50)	0.88 (0.64, 1.21)	1.46 (0.85, 2.50)	**educ & mfar(w/med)**				0.92 (0.78, 1.09)
2.63 (1.04, 6.67)	2.60 (0.99, 6.78)	2.08 (0.97, 4.48)	1.53 (0.69, 3.39)	2.53 (1.02, 6.28)	1.74 (0.81, 3.75)	**educ & exrc & mfar(w/med+ slfm)**			0.53 (0.25, 1.12)
0.42 (0.07, 2.42)	0.42 (0.07, 2.43)	0.33 (0.06, 1.76)	0.25 (0.05, 1.31)	0.41 (0.07, 2.30)	0.28 (0.05, 1.48)	0.16 (0.03, 0.99)	**cgn & ntr & exrc**		3.30 (0.63, 17.30)
0.82 (0.36, 1.85)	0.81 (0.35, 1.89)	0.65 (0.35, 1.20)	0.48 (0.25, 0.92)	0.79 (0.36, 1.74)	0.54 (0.29, 1.01)	0.31 (0.12, 0.82)	1.94 (0.33, 11.31)	**ADL & med & ntr & sst**	1.70 (0.93, 3.09)
1.39 (0.80, 2.42)	1.38 (0.76, 2.50)	1.10 (0.95, 1.28)	0.81 (0.62, 1.06)	1.34 (0.80, 2.24)	0.92 (0.78, 1.09)	0.53 (0.25, 1.12)	3.30 (0.63, 17.30)	1.70 (0.93, 3.09)	**AC**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR<1 favours the upper left intervention; a OR>1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 50 - Intervention rankings for hospitalisation medium-term analysis

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI rank	UCI rank
educ & exrc & mfar(w/med+slfm)	95.5	83.5	1.4	1	6
mfar	84.6	11.2	2.4	1	5
educ & mfar(w/med)	74.2	1.3	3.3	2	6
ac	62.6	0	4.4	3	6
mfar(w/med)	48.1	0	5.7	3	8
mfar(w/med+slfm)	36.3	0.9	6.7	2	10
mntr-mfa-	33.1	0.9	7	3	10
exrc & mfar(w/med+slfm)	33.6	0.5	7	2	10
ADL & med & ntr & sst	20.7	0.2	8.1	4	10
cgn & ntr & exrc	11.3	1.5	9	2	10

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 29 - Pairwise meta-analysis for hospitalisation: medium-term available care network (pooling comparisons with greater than one study reporting results)



Figure 30 - Comparison-adjusted funnel plot for hospitalisation: medium-term available care network

Care-home placement available care network, short-term timeframe: tables and figures

Table 51 - Short-term care-home placement available-care network

Study	Frailty	n	Experimental group	Control group	ROB					
					D1	D2	D3	D4	D5	Overall
Imhof 2012[2]	all	436	mfar	ac	-	-	x	+	-	x
Kukkonen-Harjula 2017[3]	pre-frail and frail	284	ADL & ntr & exrc	ac	+	-	x	+	-	x
Liddle 1996[4]	unclassifiable	102	aids & mfar	ac	-	x	x	+	-	xx
Metzelthin 2013[5]	frail	335	educ & mfar(w/med+slfm)	ac	-/-	-	x	+	-	x
Suijker 2016[6]	frail	1983	mfar(w/med)	ac	+/-	-	x	+	-	x
Szanton 2011[7]	pre-frail and frail	38	ADL&aids&educ&exrc& mfar(w/med+slfm)	ac	-	-	+	+	-	-
Wong 2019[8]	all	494	mfar(w/slfm)	ac	x	-	x	+	-	xx

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 52 - Results of care-home placement: short-term available care network

mfar(w/slfm)							0.99 (0.34,2.87)
5.51 (0.22,137.74)	**mfar(w/med)**						0.18 (0.01,3.75)
1.28 (0.20,8.10)	0.23 (0.01,6.90)	**mfar**					0.77 (0.17,3.50)
0.40 (0.03,4.97)	0.07 (0.00,3.25)	0.32 (0.02,4.83)	**educ & mfar(w/med+slfm)**				2.46 (0.25,23.86)
3.03 (0.10,90.43)	0.55 (0.01,46.17)	2.37 (0.07,83.33)	7.51 (0.15,388.32)	**aids & mfar**			0.33 (0.01,8.21)
0.25 (0.01,6.56)	0.04 (0.00,3.44)	0.19 (0.01,6.08)	0.61 (0.01,28.63)	0.08 (0.00,7.14)	**ADL&aids&ed&ex&mf(w/med+slfm)**		4.02 (0.18,89.76)
1.01 (0.02,58.78)	0.18 (0.00,26.13)	0.79 (0.01,52.76)	2.49 (0.03,232.77)	0.33 (0.00,53.33)	4.08 (0.03,609.32)	**ADL & ntr & exrc**	0.99 (0.02,50.04)
0.99 (0.34,2.87)	0.18 (0.01,3.75)	0.77 (0.17,3.50)	2.46 (0.25,23.86)	0.33 (0.01,8.21)	4.02 (0.18,89.76)	0.99 (0.02,50.04)	**ac**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR<1 favours the upper left intervention; a OR>1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 53 - Intervention rankings for care-home placement: short-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
mfar(w/med)	81.7	47.4	2.3	1	7
aids & mfar	70.6	30.9	3.1	1	8
mfar	56.7	4.7	4.0	1	7
mfar(w/slfm)	47.9	0.8	4.6	2	7
ac	48.6	0.1	4.6	3	7
ADL & ntr & exrc	48.5	13.5	4.6	1	8
educ & mfar(w/med+slfm)	25.8	0.9	6.2	2	8
ADL&aids&ed&mfar(w/med+slfm)	20.2	1.7	6.6	2	9

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.

Care-home placement available care network, medium-term timeframe: tables and figures

Table 54 - Medium-term care-home placement available-care network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Blom 2016[9]	all	1000	mfa-(w/med+slfm)	ac	x/+	-	x	+	-	xx
Fabacher 1994[11]	all	221	mfar(w/med)	ac	-	-	x	+	-	x
Hall 1992[12]	frail	155	hmcr & mfar(w/slfm)	hmcr & mfar	-	-	x	+	-	x
Harari 2008[13]	all	2377	mfar(w/med)	ac	+	x	x	+	+	xx
Hay 1998[14]	unclassifiable	470	mfa-	ac	-	-	x	+	-	x
Hebert 2001[15]	pre-frail and frail	464	mfar(w/med)	ac	-	-	x	+	-	x
Henderson 2005[16]	robust	130	mfar	ac	+/x	+	x	+	-	xx
Kerse 2014[17]	pre-frail and frail	3565	rsk-mfa-	ac	+/+	-	x	+	-	x
Kono 2004[18]	pre-frail and frail	107	mfar	ac	-	-	x	+	-	x
Kono 2016[19]	pre-frail	305	mfar(w/med)	mfar	+	-	x	+	-	x
Kukkonen-Harjula 2017[3]	pre-frail and frail	272	ADL & ntr & exrc	ac	+	-	x	+	-	x
Metzelthin 2013[5]	frail	313	educ & mfar(w/med+slfm)	ac	-/-	-	x	+	-	x
Monteserin Nadal 2008[20]	all	474	educ & rsk-mfa-	ac	-	-	x	+	-	x
Newbury 2001[21]	unclassifiable	94	mfa-(w/med)	ac	-	-	x	+	-	x
Newcomer 2004[22]	unclassifiable	2845	educ & mfar(w/med)	ac	-	-	x	+	-	x
Ploeg 2010[23]	pre-frail and frail	645	educ & mfar(w/med)	ac	+	-	x	+	-	x
Romera-Liebana 2018[24]	pre-frail and frail	324	cgn & med & ntr & exrc	ac	+	-	x	+	-	x
Shapiro 2002[25]	frail	67	hmcr & mfar	ac	-	-	x	+	-	xx
Suijker 2016[6]	frail	1784	mfar(w/med)	ac	+/-	-	x	+	-	x
van Hout 2010[26]	frail	443	mfar(w/med)	ac	+	-	x	+	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the

intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 55 - Results of care-home placement: medium-term available care network

rsk-mfa-													1.15 (0.77, 1.70)
1.41 (0.57, 3.50)	**mfar(w/med)**	1.97 (0.18, 22.00)											0.79 (0.42, 1.47)
2.17 (0.69, 6.83)	1.53 (0.50, 4.66)	**mfar**											0.55 (0.21, 1.48)
1.13 (0.37, 3.47)	0.80 (0.26, 2.51)	0.52 (0.14, 2.00)	**mfa-(w/med+slfm)**										1.01 (0.46, 2.26)
1.25 (0.15, 10.77)	0.89 (0.10, 7.70)	0.58 (0.06, 5.63)	1.11 (0.12, 10.63)	**mfa-(w/med)**									0.91 (0.12, 6.78)
3.58 (0.17, 77.33)	2.53 (0.12, 55.13)	1.65 (0.07, 38.98)	3.17 (0.14, 73.90)	2.86 (0.07, 109.58)	**mfa-**								0.32 (0.02, 6.23)
17.08 (1.98, 147.40)	12.08 (1.38, 105.43)	7.88 (0.81, 76.98)	15.10 (1.57, 145.41)	13.63 (0.74, 251.66)	4.77 (0.12, 182.97)	**hmcr & mfar(w/slfm)**	0.38 (0.10, 1.47)						
6.40 (1.30, 31.61)	4.53 (0.90, 22.70)	2.96 (0.51, 17.18)	5.66 (0.99, 32.31)	5.11 (0.41, 64.21)	1.79 (0.06, 50.84)	0.38 (0.09, 1.60)	**hmcr & mfar**						0.18 (0.04, 0.72)
1.93 (0.37, 9.96)	1.36 (0.26, 7.15)	0.89 (0.15, 5.39)	1.70 (0.29, 10.14)	1.54 (0.12, 19.89)	0.54 (0.02, 15.64)	0.11 (0.01, 1.46)	0.30 (0.04, 2.49)	**educ & rsk-mfa-**					0.59 (0.14, 2.52)
0.52 (0.08, 3.26)	0.37 (0.06, 2.34)	0.24 (0.03, 1.74)	0.46 (0.07, 3.28)	0.42 (0.03, 6.12)	0.15 (0.00, 4.67)	0.03 (0.00, 0.45)	0.08 (0.01, 0.79)	0.27 (0.03, 2.70)	**educ & mfar(w/med +slfm)**				2.19 (0.42, 11.48)
0.93 (0.36, 2.39)	0.66 (0.25, 1.75)	0.43 (0.13, 1.42)	0.83 (0.26, 2.66)	0.75 (0.08, 6.57)	0.26 (0.01, 5.72)	0.05 (0.01, 0.48)	0.15 (0.03, 0.74)	0.48 (0.09, 2.59)	1.79 (0.28, 11.50)	**educ & mfar(w/med)**			1.14 (0.34, 3.82)
1.77 (0.25, 12.67)	1.25 (0.17, 9.07)	0.82 (0.10, 6.69)	1.57 (0.19, 12.62)	1.42 (0.09, 22.80)	0.50 (0.01, 17.05)	0.10 (0.01, 1.68)	0.28 (0.03, 2.98)	0.92 (0.08, 10.21)	3.39 (0.27, 43.01)	1.90 (0.26, 13.96)	**cgn & med & ntr & exrc**		0.65 (0.11, 3.92)
1.20 (0.14, 10.03)	0.85 (0.10, 7.18)	0.55 (0.06, 5.25)	1.06 (0.11, 9.91)	0.96 (0.05, 17.27)	0.33 (0.01, 12.61)	0.07 (0.00, 1.27)	0.19 (0.02, 2.30)	0.62 (0.05, 7.87)	2.29 (0.16, 32.93)	1.28 (0.15, 11.03)	0.68 (0.04, 10.66)	**ADL & ntr & exrc**	0.96 (0.13, 6.89)
1.15 (0.62, 2.13)	0.81 (0.42, 1.57)	0.53 (0.20, 1.39)	1.01 (0.40, 2.58)	0.91 (0.12, 7.18)	0.32 (0.02, 6.48)	0.07 (0.01, 0.53)	0.18 (0.04, 0.78)	0.59 (0.13, 2.72)	2.19 (0.39, 12.29)	1.23 (0.61, 2.49)	0.65 (0.10, 4.17)	0.96 (0.13, 7.29)	**ac**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR<1 favours the upper left intervention; a OR>1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 56 - Intervention rankings for care-home placement: medium-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & mfar(w/slfm)	95.1	65.1	1.6	1	5
hmcr & mfar	85.2	4.6	2.9	1	7
mfa-	67	19.9	5.3	1	14
mfar	63.9	0.5	5.7	2	12
educ & rsk-mfa-	56.6	1.7	6.6	2	14
cgn & med & ntr & exrc	52.6	3.2	7.2	1	14
mfar(w/med)	48.1	0	7.7	4	12
mfa-(w/med)	43.6	2.8	8.3	2	14
adl & ntr & exrc	41.3	2.1	8.6	2	14
ac	37	0	9.2	6	12
mfa-(w/med+slfm)	36.5	0	9.3	4	14
rsk-mfa-	30.6	0	10	6	14
educ & mfar(w/med)	27.6	0	10.4	5	14
educ & mfar(w/med+slfm)	15	0.1	12.1	4	14

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 31 - Pairwise meta-analysis for care-home placement: medium-term available care network (pooling comparisons with greater than one study reporting results)



Figure 32 - Comparison-adjusted funnel plot for care-home placement: medium-term available care network

Care-home placement available care network, long-term timeframe: tables and figures

Table 57 - Long-term care-home placement available-care network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Carpenter 1990[27]	all	395	rsk-mfa-	ac	-	-	x	+	-	x
Fischer 2009[28]	all	3700	eng & mfa-(w/slfm)	ac	+	-	x	+	-	x
Ford 1971[29]	pre-frail and frail	213	mfar(w/med)	ac	+	-	x	+	-	x
Hay 1998[14]	unclassifiable	359	mfa-	ac	-	-	x	+	-	x
Kerse 2014[17]	pre-frail and frail	3305	rsk-mfa-	ac	+/+	-	x	+	-	x
Kono 2016[19]	pre-frail	280	mfar(w/med)	mfar	+	-	x	+	-	x
Kukkonen-Harjula 2017[3]	pre-frail and frail	262	ADL & ntr & exrc	ac	+	-	x	+	+	x
Metzelthin 2013[5]	frail	290	educ & mfar(w/med+slfm)	ac	-/-	-	x	+	-	x
Stuck 1995[30]	all	364	educ & mfar(w/med)	ac	+	-	x	+	-	x
Stuck 2015[31]	robust and pre-frail	2045	educ & mfar(w/med+slfm)	ac	+	x	x	+	+	xx
Suijker 2016[6]	frail	1776	mfar(w/med)	ac	+/-	-	x	+	-	x
Thomas 2007[69]	pre-frail and frail	341	mfar(w/med)	ac	-	-	-	+	-	-
Tomita 2007[32]	frail	85	aids	ac	x	-	x	+	-	xx
Tulloch 1979[33]	all	223	mfar(w/med)	ac	-	-	x	+	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 58 - Results of care-home placement: long-term available care network

rsk-mfa-									0.75 (0.10, 5.72)
1.31 (0.80,2.14)	**mfar(w/med)**	2.63 (0.50, 13.80)							1.08 (0.70, 1.65)
3.44 (0.61,19.37)	2.63 (0.50,13.80)	**mfar**							
2.16 (0.22,21.36)	1.65 (0.16,16.64)	0.63 (0.04,10.78)	**mfa-**						0.65 (0.07, 6.34)
1.16 (0.70,1.95)	0.89 (0.49,1.61)	0.34 (0.06,1.97)	0.54 (0.05,5.46)	**eng & mfa-(w/slfm)**					1.21 (0.79, 1.86)
1.12 (0.56,2.23)	0.86 (0.41,1.81)	0.33 (0.05,2.00)	0.52 (0.05,5.48)	0.96 (0.45,2.06)	**educ & mfar(w/med+slfm)**				1.26 (0.67, 2.37)
1.83 (0.58,5.77)	1.40 (0.43,4.57)	0.53 (0.07,4.08)	0.85 (0.07,10.66)	1.57 (0.48,5.17)	1.64 (0.46,5.88)	**educ & mfar(w/med)**			0.77 (0.25, 2.33)
3.56 (0.35,36.28)	2.72 (0.26,28.26)	1.03 (0.06,18.19)	1.65 (0.06,41.96)	3.05 (0.29,31.84)	3.18 (0.29,34.70)	1.94 (0.15,25.06)	**aids**		0.40 (0.04, 3.97)
1.78 (0.68,4.65)	1.36 (0.50,3.71)	0.52 (0.07,3.59)	0.82 (0.07,9.57)	1.53 (0.56,4.21)	1.59 (0.52,4.84)	0.97 (0.23,4.10)	0.50 (0.04,5.98)	**ADL & ntr & exrc**	0.79 (0.32, 1.98)
1.41 (1.06,1.88)	1.08 (0.72,1.62)	0.41 (0.07,2.26)	0.65 (0.07,6.34)	1.21 (0.79,1.86)	1.26 (0.67,2.37)	0.77 (0.25,2.33)	0.40 (0.04,3.97)	0.79 (0.32,1.98)	**ac**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR<1 favours the upper left intervention; a OR>1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 59 - Intervention rankings for care-home placement: long-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
mfar	76.5	31.2	3.1	1	10
aids	74.2	37.6	3.3	1	10
adl & ntr & exrc	60.5	3.7	4.6	1	10
educ & mfar(w/med)	60.2	6	4.6	1	10
mfa-	58.8	21.2	4.7	1	10
ac	50.7	0	5.4	3	8
mfar(w/med)	42.4	0.1	6.2	3	10
eng & mfa-(w/slfm)	29.9	0	7.3	3	10
educ & mfar(w/med+slfm)	29.1	0.2	7.4	3	10
rsk-mfa	17.7	0	8.4	6	10

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 33 - Pairwise meta-analysis for care-home placement: long-term available care network (pooling comparisons with greater than one study reporting results)

Table 60 - Medium-term care-home placement homecare network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Fernandez-Barres 2017[34]	frail	129	hmcr & ntr	hmcr	+	-	x	+	-	x
Lewin 2013[38]	frail	607	hmcr & educ & mfar	hmcr	x	x	x	+	-	xx
Rooijackers 2021[37]	frail	232	hmcr & ADL & mfar(w/slfm)	hmcr	+/-	-	x	+	-	x
Wolter 2013[39]	frail	599	hmcr & mfar(w/med)	hmcr	+/-	-	x	+	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 61 - Results of care-home placement: medium-term homecare network

hmcr & ntr				1.37 (0.48,3.98)
1.22 (0.39,3.82)	**hmcr & mfar(w/med)**			1.13 (0.75,1.70)
1.59 (0.50,5.03)	1.30 (0.71,2.38)	**hmcr & educ & mfar**		0.86 (0.55,1.35)
1.51 (0.37,6.25)	1.24 (0.44,3.45)	0.95 (0.34,2.69)	**hmcr & ADL & mfar(w/slfm)**	0.91 (0.35,2.33)
1.37 (0.48,3.98)	1.13 (0.75,1.70)	0.86 (0.55,1.35)	0.91 (0.35,2.33)	**hmcr**

Lower left triangle presents the findings (OR with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (OR with 95% CI) of pairwise meta-analyses. A OR<1 favours the upper left intervention; a OR>1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (OR and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 62 - Intervention rankings for care-home placement: medium-term homecare network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & educ & mfar	71.2	36.4	2.2	1	5
hmcr & ADL & mfar(w/slfm)	60.1	38.1	2.6	1	5
hmcr	52.5	6.8	2.9	1	5
hmcr & mfar(w/med)	35.8	4.9	3.6	1	5
hmcr & ntr	30.4	13.8	3.8	1	5

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.

Health status (available care network, medium-term timeframe only)

Table 63 - Medium-term health status available-care network

Study	Frailty	n	Experimental group	Control group	ROB					
					D1	D2	D3	D4	D5	Overall
Blom 2016[9]	all	844	mfa-(w/med+slfm)	ac	x/+	-	x	-	+	xx
Bouman 2008[44]	pre-frail and frail	293	mfar(w/med)	ac	+	-	x	-	-	x
Brettschneider 2015[45]	frail	278	mfar(w/med)	ac	-	-	x	-	+	x
Cameron 2013[59]	frail	215	exrc & mfar(w/med+slfm)	ac	+	-	-	-	+	-
Serra-Prat 2017[60]	pre-frail	133	ntr & exrc	ac	-	-	x	-	-	x
Szanton 2019[49]	pre-frail and frail	260	ADL&aids&educ&exrc& mfar(w/med+slfm)	ac	+	-	x	-	-	x
Takahashi 2012[57]	frail	166	mntr-mfa-	ac	-	-	x	-	+	x
Thomas 2007[69]	pre-frail and frail	442	mfar(w/med)	ac	-	-	x	-	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 64 - Results of Health status: medium-term available care network

ntr & exrc						0.07 (-0.27,0.41)
0.17 (-0.36,0.71)	**mntr-mfa-**					-0.11 (-0.41,0.20)
-0.04 (-0.47,0.38)	-0.21 (-0.61,0.19)	**mfar(w/med)**				0.11 (-0.06,0.28)
-0.00 (-0.47,0.46)	-0.18 (-0.62,0.27)	0.04 (-0.27,0.34)	**mfa-(w/med+slfm)**			0.07 (-0.09,0.23)
0.08 (-0.44,0.59)	-0.10 (-0.59,0.40)	0.12 (-0.25,0.49)	0.08 (-0.34,0.50)	**exrc & mfar(w/med+slfm)**		-0.01 (-0.28,0.26)
0.13 (-0.37,0.63)	-0.04 (-0.52,0.44)	0.17 (-0.18,0.53)	0.14 (-0.27,0.54)	0.05 (-0.40,0.51)	**ADL&aids&ed&ex&mf(w/med+slfm)**	-0.06 (-0.31,0.18)
0.07 (-0.33,0.46)	-0.11 (-0.47,0.26)	0.11 (-0.06,0.28)	0.07 (-0.18,0.32)	-0.01 (-0.34,0.32)	-0.06 (-0.38,0.25)	**ac**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 65 - Intervention rankings for Health status: medium-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
mfar(w/med)	74.1	24.4	2.6	1	6
mfa-(w/med+slfm)	64	22.3	3.2	1	7
ntr & exrc	59.2	27.4	3.4	1	7
exrc & mfar(w/med+slfm)	44.7	12.3	4.3	1	7
ac	44.1	0.2	4.4	2	6
adl&aids&ed&ex&mf(w/med+slfm)	35	6.6	4.9	1	7
mntr-mfa-	28.9	6.8	5.3	1	7

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 34 - Pairwise meta-analysis for Health status: medium-term available care network (pooling comparisons with greater than one study reporting results)



Figure 35 - Example of disconnected network for health status medium-term available care network



Figure 36 - Rankogram showing comparative effectiveness of interventions for Health Status medium-term available care network. Results based on a simulation of 1000 replications



Figure 37 - Network plot for risk of bias analysis for Health Status medium-term available care network

Table 66 - Results of Risk of Bias analysis for Health Status: medium-term available care network

ntr & exrc					0.07 (-0.27, 0.41)
0.17 (-0.36,0.71)	**mntr-mfa-**				-0.11 (-0.41, 0.20)
-0.04 (-0.47,0.38)	-0.21 (-0.61,0.19)	**mfar(w/med)**			0.11 (-0.06, 0.28)
0.08 (-0.44,0.59)	-0.10 (-0.59,0.40)	0.12 (-0.25,0.49)	**exrc & mfar(w/med+slfm)**		-0.01 (-0.28, 0.26)
0.13 (-0.37,0.63)	-0.04 (-0.52,0.44)	0.17 (-0.18,0.53)	0.05 (-0.40,0.51)	**ADL&aids&ed&ex&mf(w/med+slfm)**	-0.06 (-0.31, 0.18)
0.07 (-0.33,0.46)	-0.11 (-0.47,0.26)	0.11 (-0.06,0.28)	-0.01 (-0.34,0.32)	-0.06 (-0.38,0.25)	**AC**



Figure 38 - Rankogram showing comparative effectiveness of interventions for risk of bias sensitivity analysis for Health Status medium-term available care network. Results based on a simulation of 1000 replications

Depression: available care network (medium-term timeframe only)

Table 67 - Medium-term depression available-care network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Bleijenberg 2016[56]	pre-frail and frail	2489	rsk-mfa-	ac	x/+	-	x	+	-	xx
Blom 2016[9]	all	1379	mfa-(w/med+slfm)	ac	x/+	-	x	-	-	xx
Bouman 2008[44]	pre-frail and frail	293	mfar(w/med)	ac	+	-	x	-	-	x
Cameron 2013[59]	frail	214	exrc & mfar(w/med+slfm)	ac	+	-	-	-	+	-
Clark 1997[40]	robust and pre-frail	283	eng & educ	ac	x	-	x	-	x	xx
Cutchin 2009[70]	unclassifiable	110	mfar	ac	-	-	x	-	-	x
Gustafson 2021[71]	all	390	aids & educ & comm	ac	+	-	x	-	-	x
Henderson 2005[16]	robust	124	mfar	ac	+/x	+	x	+	-	xx
Kono 2016[19]	pre-frail	360	mfar(w/med)	mfar	+	-	x	-	-	x
Metzelthin 2013[5]	frail	317	educ & mfar(w/med+slfm)	ac	-/-	-	x	-	-	x
Newbury 2001[21]	unclassifiable	89	mfa-(w/med)	ac	-	-	x	-	-	x
Rubenstein 2007[48]	frail	694	mfar(w/med)	ac	-	-	-	-	-	-
Szanton 2019[49]	pre-frail and frail	260	ADL&aids&educ&exrc& mfar(w/med+slfm)	ac	+	-	x	-	-	x
Takahashi 2012[57]	frail	166	mntr-mfa-	ac	-	-	x	-	+	x
van Heuvelen 2005[50]	pre-frail and frail	77	exrc & psyc	ac	-	x	x	-	-	xx

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 68 - Results of Depression: medium-term available care network

rsk-mfa-												-0.09 (-0.18, -0.00)
-0.09 (-0.52,0.34)	**mntr-mfa-**											0.00 (-0.31, 0.31)
-0.02 (-0.31,0.27)	0.07 (-0.34,0.48)	**mfar(w/med)**	0.00 (-0.21, 0.21)									-0.13 (-0.26, -0.00)
-0.13 (-0.46,0.20)	-0.04 (-0.48,0.40)	-0.11 (-0.33,0.12)	**mfar**									0.15 (-0.19, 0.49)
-0.09 (-0.42,0.24)	-0.00 (-0.44,0.44)	-0.07 (-0.37,0.24)	0.04 (-0.30,0.38)	**mfa-(w/med+slfm)**								0.00 (-0.13, 0.13)
-0.20 (-0.72,0.31)	-0.11 (-0.71,0.48)	-0.18 (-0.68,0.32)	-0.07 (-0.60,0.45)	-0.11 (-0.64,0.41)	**mfa-(w/med)**							0.11 (-0.30, 0.53)
-0.03 (-0.60,0.55)	0.06 (-0.58,0.71)	-0.00 (-0.57,0.56)	0.10 (-0.48,0.68)	0.06 (-0.52,0.65)	0.18 (-0.53,0.88)	**exrc & psyc**						-0.06 (-0.55, 0.43)
0.02 (-0.38,0.43)	0.11 (-0.39,0.61)	0.04 (-0.34,0.43)	0.15 (-0.26,0.57)	0.11 (-0.31,0.53)	0.23 (-0.35,0.80)	0.05 (-0.58,0.68)	**exrc & mfar(w/med+slfm)**					-0.11 (-0.38, 0.16)
0.05 (-0.35,0.44)	0.13 (-0.35,0.62)	0.07 (-0.30,0.44)	0.17 (-0.23,0.58)	0.13 (-0.27,0.54)	0.25 (-0.32,0.81)	0.07 (-0.55,0.69)	0.02 (-0.44,0.49)	**eng & educ**				-0.13 (-0.38, 0.11)
-0.26 (-0.63,0.12)	-0.17 (-0.64,0.31)	-0.24 (-0.59,0.12)	-0.13 (-0.51,0.26)	-0.17 (-0.56,0.22)	-0.05 (-0.61,0.50)	-0.23 (-0.84,0.38)	-0.28 (-0.73,0.18)	-0.30 (-0.74,0.14)	**educ & mfar(w/med+slfm)**			0.17 (-0.05, 0.39)
-0.04 (-0.40,0.32)	0.05 (-0.42,0.51)	-0.02 (-0.36,0.32)	0.09 (-0.29,0.46)	0.05 (-0.33,0.42)	0.16 (-0.38,0.71)	-0.02 (-0.62,0.59)	-0.06 (-0.51,0.38)	-0.09 (-0.52,0.34)	0.21 (-0.20,0.63)	**aids & educ & comm**		-0.05 (-0.24, 0.15)
-0.08 (-0.47,0.31)	0.01 (-0.48,0.50)	-0.06 (-0.43,0.31)	0.05 (-0.35,0.45)	0.01 (-0.39,0.41)	0.12 (-0.44,0.69)	-0.05 (-0.67,0.56)	-0.10 (-0.57,0.36)	-0.12 (-0.58,0.33)	0.18 (-0.26,0.62)	-0.04 (-0.47,0.39)	**ADL&aids&ed&ex&mf(w/med+slfm)**	-0.01 (-0.25, 0.23)
-0.09 (-0.31,0.14)	-0.00 (-0.37,0.37)	-0.07 (-0.25,0.12)	0.04 (-0.20,0.28)	-0.00 (-0.24,0.24)	0.11 (-0.35,0.58)	-0.06 (-0.59,0.47)	-0.11 (-0.45,0.23)	-0.13 (-0.46,0.19)	0.17 (-0.13,0.47)	-0.05 (-0.33,0.24)	-0.01 (-0.33,0.31)	**ac**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD<1 favours the upper left intervention; a SMD>1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 69 - Intervention rankings for Depression: medium-term available care network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
eng & educ	69.2	20.2	4.7	1	12
exrc & mfar(w/med+slfm)	67.7	18.7	4.9	1	12
rsk-mfa-	64.2	7.7	5.3	1	11
mfar(w/med)	62.1	2.9	5.6	1	11
aids & educ & comm	56.4	6.9	6.2	1	13
exrc & psyc	56.4	21.1	6.2	1	13
ADL&aids&ed&ex&mf(w/med+slfm)	48.4	5.7	7.2	1	13
mntr-mfa-	47.7	8.6	7.3	1	13
mfa-(w/med+slfm)	45.5	2.3	7.5	2	13
ac	45.1	0	7.6	5	11
mfar	36.5	1.3	8.6	2	13
mfa-(w/med)	31.1	4.2	9.3	1	13
educ & mfar(w/med+slfm)	19.7	0.4	10.6	3	13

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 39 - Pairwise meta-analysis for depression: medium-term available care network (pooling comparisons with greater than one study reporting results)



Figure 40 - Rankogram showing comparative effectiveness of interventions for depression medium-term available care network. Results based on a simulation of 1000 replications.



Figure 41 - Comparison-adjusted funnel plot for depression: medium-term available care network



Figure 42 - Network plot for risk of bias analysis for depression medium-term available care network

Table 70 - Intervention rankings for risk of bias analysis for depression: medium-term available care network

Treatment	SUCRA	PrBest	Mean Rank	95% CI for true rank
mfar(w/med)	77.8	16.0	2.8	1 - 6
exrc & mfar(w/med+slfm)	69.9	30.4	3.4	1 - 8
mfar	69.0	17.9	3.5	1 - 8
aids & educ & comm	56.7	8.9	4.5	1 - 8
ADL&aids&ed&ex&mf(w/med+slfm)	47.9	9.0	5.2	1 - 9
mntr-mfa-	46.1	10.4	5.3	1 - 9
ac	42.0	0.0	5.6	3 - 8
mfa-(w/med)	27.5	7.1	6.8	1 - 9
educ & mfar(w/med+slfm)	13.1	0.3	8.0	4 - 9



Figure 43 - Rankogram showing comparative effectiveness of interventions for risk of bias sensitivity analysis for depression medium-term available care network. Results based on a simulation of 1000 replications.

Table 71 - Results of risk of bias depression: medium-term available care network

mntr-mfa-								0.00 (-0.31, 0.31)
0.12 (-0.20,0.45)	**mfar(w/med)**	0.00 (-0.21, 0.21)						-0.13 (-0.26, -0.00)
0.10 (-0.27,0.47)	-0.02 (-0.21,0.16)	**mfar**						-0.03 (-0.40, 0.35)
-0.11 (-0.63,0.40)	-0.24 (-0.67,0.20)	-0.22 (-0.68,0.25)	**mfa-(w/med)**					0.11 (-0.30, 0.53)
0.11 (-0.30,0.52)	-0.01 (-0.31,0.28)	0.01 (-0.33,0.35)	0.23 (-0.27,0.72)	**exrc & mfar(w/med+slfm)**				-0.11 (-0.38, 0.16)
-0.17 (-0.55,0.21)	-0.29 (-0.54,-0.04)	-0.27 (-0.57,0.03)	-0.05 (-0.52,0.42)	-0.28 (-0.63,0.07)	**educ & mfar(w/med+slfm)**			0.17 (-0.05, 0.39)
0.05 (-0.32,0.41)	-0.08 (-0.31,0.16)	-0.05 (-0.34,0.23)	0.16 (-0.30,0.62)	-0.06 (-0.40,0.27)	0.21 (-0.08,0.51)	**aids & educ & comm**		-0.05 (-0.24, 0.15)
0.01 (-0.38,0.40)	-0.11 (-0.38,0.16)	-0.09 (-0.41,0.23)	0.12 (-0.36,0.61)	-0.10 (-0.46,0.26)	0.18 (-0.15,0.51)	-0.04 (-0.35,0.28)	**ADL&aids&ed&ex&mf(w/med+slfm)**	-0.01 (-0.25, 0.23)
-0.00 (-0.31,0.31)	-0.12 (-0.24,-0.00)	-0.10 (-0.30,0.10)	0.11 (-0.30,0.53)	-0.11 (-0.38,0.16)	0.17 (-0.05,0.39)	-0.05 (-0.24,0.15)	-0.01 (-0.25,0.23)	**AC**

Depression: homecare network (medium-term timeframe only)

Table 72 - Medium-term depression homecare network

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Bernabei 1998[54]	frail	199	hmcr & mfar(w/med)	hmcr	-	-	x	-	-	x
Fernandez-Barres 2017[34]	frail	111	hmcr & ntr	hmcr	+	-	x	-	-	x
Parsons M 2012[53]	frail	251	hmcr & mfar	hmcr & mfa-	+/-	-	x	-	-	x
Parsons M 2017[36]	frail	113	hmcr & ADL & mfar(w/slfm)	hmcr & mfa-	-	-	x	-	-	xx
Rooijackers 2021[37]	frail	264	hmcr & ADL & mfar(w/slfm)	hmcr	+/-	-	x	+	x	xx
Teut 2013[62]	frail	58	hmcr & hmnt & exrc	hmcr	+/+	-	x	-	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only).

Table 73 - Results of Depression: medium-term homecare network

hmcr & ntr						-0.24 (-0.62,0.14)
0.14 (-0.33,0.61)	**hmcr & mfar(w/med)**					-0.38 (-0.66,-0.10)
-0.34 (-0.97,0.29)	-0.48 (-1.06,0.10)	**hmcr & mfar**	0.19 (-0.06,0.44)			
-0.15 (-0.73,0.43)	-0.29 (-0.81,0.23)	0.19 (-0.06,0.44)	**hmcr & mfa-**		-0.00 (-0.37,0.36)	
-0.18 (-0.82,0.46)	-0.32 (-0.90,0.27)	0.17 (-0.56,0.89)	-0.03 (-0.70,0.65)	**hmcr & hmnt & exrc**		-0.06 (-0.58,0.45)
-0.16 (-0.60,0.29)	-0.29 (-0.66,0.08)	0.19 (-0.26,0.63)	-0.00 (-0.37,0.36)	0.02 (-0.55,0.59)	**hmcr & ADL & mfar(w/slfm)**	-0.09 (-0.33,0.16)
-0.24 (-0.62,0.14)	-0.38 (-0.66,-0.10)	0.10 (-0.40,0.61)	-0.09 (-0.53,0.35)	-0.06 (-0.58,0.45)	-0.09 (-0.33,0.16)	**hmcr**

Lower left triangle presents the findings (SMD with 95% CI) of the network meta-analysis. Upper right triangle presents the findings (SMD with 95% CI) of pairwise meta-analyses. A SMD>1 favours the upper left intervention; a SMD<1 favours the lower right intervention. Within the table, comparisons between treatments should be read from left to right (i.e. treatment 1 versus treatment 2). The estimate effect measure (SMD and their 95% CI) is in the cell in common between the row- and column-defining treatment.

Table 74 - Intervention rankings for Depression: medium-term homecare network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & mfar(w/med)	89.1	58.8	1.7	1	4
hmcr & ntr	69.7	22.3	2.8	1	7
hmcr & mfa-	50.0	7.2	4	1	6
hmcr & ADL & mfar(w/slfm)	49.4	1.3	4	2	7
hmcr & hmnt & exrc	43.9	9.9	4.4	1	7
hmcr	30.2	0	5.2	3	7
hmcr & mfar	17.8	0.5	5.9	2	7

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 44 - Rankogram showing comparative effectiveness of interventions for depression medium-term homecare network. Results based on a simulation of 1000 replications.



Figure 45 - Network plot for risk of bias analysis for depression medium-term homecare network

Table 75 - Intervention rankings for risk of bias analysis for depression: medium-term homecare network

Treatment	SUCRA	PrBest	Mean Rank	95% CI for true rank
hmcr & mfar(w/med)	86.1	64.2	1.4	1 - 3
hmcr & ntr	62.1	24.2	2.1	1 - 4
hmcr & hmnt & exrc	34.6	11.6	3	1 - 4
hmcr	17.2	0	3.5	2 - 4



Figure 46 - Rankogram showing comparative effectiveness of interventions for risk of bias sensitivity analysis for depression medium-term homecare network. Results based on a simulation of 1000 replications.

Table 76 - Results of risk of bias depression: medium-term homecare network

hmcr	0.24 (-0.14,0.62)	0.38 (0.10,0.66)	0.06 (-0.45,0.58)
0.24 (-0.14,0.62)	**hmcr & ntr**		
0.38 (0.10,0.66)	0.14 (-0.33,0.61)	**hmcr & mfar(w/med)**	
0.06 (-0.45,0.58)	-0.18 (-0.82,0.46)	-0.32 (-0.90,0.27)	**hmcr & hmnt & exrc**

Mortality: medium-term timeframe only

Table 77 - Medium-term mortality

					ROB					
Study	**Frailty**	**n**	**Experimental group**	**Control group**	**D1**	**D2**	**D3**	**D4**	**D5**	**Overall**
Alegria 2019[72]	pre-frail	267	exrc & psyc	ac	x	x	x	+	-	xx
Auvinen 2020[52]	frail	494	hmcr & med	hmcr	+	-	x	+	+	x
Barenfeld 2018[73]	all	125	educ	ac	-	x	x	+	-	xx
Bernabei 1998[54]	frail	199	hmcr & mfar(w/med)	hmcr	-	-	+	+	+	-
Bleijenberg 2016[56]	pre-frail and frail	3092	rsk-mfa-	ac	x/+	-	+	+	-	x
Blom 2016[9]	all	1095	mfa-(w/med+slfm)	ac	x/+	-	x	+	-	xx
Borrows 2013[74]	unclassifiable	33	aids	mfa-	+	-	x	+	-	x
Bouman 2008[44]	pre-frail and frail	311	mfar(w/med)	ac	+	-	x	+	+	x
Brettschneider 2015[45]	frail	278	mfar(w/med)	ac	-	-	x	+	+	x
Cameron 2013[59]	frail	238	exrc & mfar(w/med+slfm)	ac	+	-	-	+	+	-
Coleman 1999[75]	frail	164	educ & mfar(w/med+slfm)	ac	-/-	-	x	+	-	x
Counsell 2007[76]	unclassifiable	853	educ & mfar(w/med+slfm)	ac	+/-	-	x	+	+	x
Dalby 2000[10]	frail	139	mfar(w/med)	ac	-	-	+	+	+	-
de Craen 2006[77]	all	335	mfa-	ac	+	-	x	+	-	x
Dorresteijn 2016[46]	unclassifiable	389	ADL	ac	+	-	+	+	-	-

Fabacher 1994[11]	all	229	mfar(w/med)	ac	-	-	x	+	+	x
Fernandez-Barres 2017[34]	frail	147	hmcr & ntr	hmcr	+	-	x	+	-	x
Fristedt 2019[78]	frail	62	hmcr & mfar(w/med)	hmcr	x	-	+	+	+	x
Gill 2002[79]	pre-frail and frail	188	ADL & exrc	ac	-	-	+	+	+	-
Gitlin 2006[41]	pre-frail and frail	319	ADL & aids & exrc	ac	+	-	+	+	+	-
Gustafsson 2013[80]	all	288	educ & mfa-	ac	-	-	x	+	-	x
Hall 1992[12]	frail	167	hmcr & mfar(w/slfm)	hmcr & mfar	-	-	+	+	+	-
Harari 2008[13]	all	2423	mfar(w/med)	ac	+	x	x	+	+	xx
Hay 1998[14]	unclassifiable	484	mfa-	ac	-	-	x	+	-	x
Hebert 2001[15]	pre-frail and frail	494	mfar(w/med)	ac	-	-	-	+	-	-
Henderson 2005[16]	robust	130	mfar	ac	+/x	+	x	+	-	xx
Hendriksen 1984[63]	all	572	mfar	ac	-	-	+	+	+	-
Hogg 2009[81]	unclassifiable	240	mfar(w/med)	ac	-	-	-	+	-	-
Holland 2005[82]	unclassifiable	493	educ & exrc & mfar(w/slfm)	ac	+	-	x	+	-	x
Howel 2019[83]	all	725	wlfr	ac	+	+	x	+	+	x
Kerse 2014[17]	pre-frail and frail	3687	rsk-mfa-	ac	+/+	-	x	+	-	x
Kono 2004[18]	pre-frail and frail	117	mfar	ac	-	-	-	+	-	-
Kono 2016[19]	pre-frail	351	mfar(w/med)	mfar	+	-	x	+	+	x
Kukkonen-Harjula 2017[3]	pre-frail and frail	287	ADL & ntr & exrc	ac	+	-	x	+	-	x
Leveille 1998[64]	unclassifiable	191	educ & exrc & mfar(w/med+slfm)	ac	+	-	x	+	-	x
Lewin 2013[38]	frail	750	hmcr & educ & mfar	hmcr	x	x	+	+	+	xx
Liimatta 2019[84]	robust and pre-frail	422	exrc & mfa-(w/med)	ac	-	-	+	+	+	-
Mann WC 1999[55]	frail	100	hmcr & aids	hmcr	-	-	-	+	-	-
Meng 2005[85]	frail	599	vchr	ac	-	x	x	+	x	xx
Metzelthin 2013[5]	frail	321	educ & mfar(w/med+slfm)	ac	-/-	-	x	+	-	x
Monteserin Nadal 2008[20]	all	516	educ & rsk-mfa-	ac	-	-	x	+	+	x
Morey 2009[86]	unclassifiable	362	exrc	ac	-	-	x	+	-	x
Newbury 2001[21]	unclassifiable	100	mfa-(w/med)	ac	-	-	+	+	+	-
Newcomer 2004[22]	unclassifiable	2934	educ & mfar(w/med)	ac	-	-	x	+	-	x
Ng 2015[65]	pre-frail and frail	95	cgn & ntr & exrc	ac	+	-	x	+	+	x
Parsons M 2012[53]	frail	196	hmcr & mfar	hmcr & mfa-	+/-	-	x	+	-	x
Parsons M 2017[36]	frail	75	hmcr & ADL & mfar(w/slfm)	hmcr & mfa-	-	-	x	+	+	x
Ploeg 2010[23]	pre-frail and frail	713	educ & mfar(w/med)	ac	+	-	-	+	-	-
Rockwood 2000[43]	frail	182	mfa-(w/med)	ac	-	-	+	+	+	-
Romera-Liebana 2018[24]	pre-frail and frail	342	cgn & med & ntr & exrc	ac	+	-	x	+	-	x
Rooijackers 2021[37]	frail	252	hmcr & ADL & mfar(w/slfm)	hmcr	+/-	-	-	+	-	-
Rubenstein 2007[48]	frail	792	mfar(w/med)	ac	-	-	+	+	+	-
Serra-Prat 2017[60]	pre-frail	172	ntr & exrc	ac	-	-	+	+	-	-
Shapiro 2002[25]	frail	58	hmcr & mfar	ac	-	x	x	+	-	xx
Siemonsma 2018[87]	frail	118	ADL	mfa-	-	-	x	+	-	x
Suijker 2016[6]	frail	2283	mfar(w/med)	ac	+/-	-	+	+	+	-
Szanton 2019[49]	pre-frail and frail	273	ADL&aids&educ&exrc& mfar(w/med+slfm)	ac	+	-	x	+	-	x
Takahashi 2012[57]	frail	186	mntr-mfa-	ac	-	-	x	+	-	x
Teut 2013[62]	frail	55	hmcr & hmnt & exrc	hmcr	+/+	-	-	+	-	-
van Hout 2010[26]	frail	651	mfar(w/med)	ac	+	-	+	+	+	-
van Rossum 1993[68]	all	580	mfar	ac	-	-	+	+	+	-
Vass 2005[88]	all	4060	mfar(w/med)	mfar	+/+	-	+	+	+	-
Williams 1992[89]	all	470	mfar	mfa-	-	-	+	+	+	-
Wolter 2013[39]	frail	732	hmcr & mfar(w/med)	hmcr	+/-	-	x	+	-	x
Yamada 2003[90]	pre-frail and frail	356	mfar(w/med)	ac	+	-	x	+	-	x

n: number of participants. ROB: risk of bias. D#: Domain #. D1: risk of bias arising from the randomisation process (individual); or, for cluster trials, risk of bias arising from the randomisation process / risk of bias arising from the identification or recruitment of participants into clusters. D2: risk of bias due to deviations from the intended interventions (effect of assignment to the intervention). D3: risk of bias due to missing outcome data. D4: risk of bias in measurement of the outcome. D5: risk of bias in selection of the reported result. +: low risk of bias; -: some concerns; x: high risk of bias / serious concerns; xx: very serious concerns (overall risk of bias only). all: robust, pre-frail and frail.

Table 78 - Results of mortality: medium-term network

Please note: the results of mortality: medium-term network are too large to fit on one page. Please refer to Supplementary Material 8: NMA estimate and rank tables: sheet mort-t2-all.

wlfr																																								0.80 (0.30, 2.18)
0.78 (0.25, 2.49)	vchr																																							1.02 (0.61, 1.73)
0.78 (0.27, 2.25)	1.00 (0.53, 1.87)	rsk-mfa-																																						1.03 (0.79, 1.33)
3.57 (0.14, 89.42)	4.56 (0.20, 101.89)	4.56 (0.21, 98.30)	ntr & exrc																																					0.22 (0.01, 4.75)
0.18 (0.04, 0.83)	0.23 (0.06, 0.83)	0.23 (0.07, 0.75)	0.05 (0.00, 1.32)	mntr-mfa-																																				4.49 (1.43, 14.10)
0.93 (0.33, 2.62)	1.19 (0.66, 2.15)	1.19 (0.83, 1.70)	0.26 (0.01, 5.58)	5.21 (1.61, 16.89)	mfar(w/med)	0.99 (0.73, 1.36)																																		0.88 (0.66, 1.17)
0.91 (0.32, 2.63)	1.17 (0.62, 2.19)	1.17 (0.77, 1.77)	0.26 (0.01, 5.52)	5.11 (1.55, 16.89)	0.98 (0.74, 1.30)	mfar			0.74 (0.44, 1.24)																															1.07 (0.70, 1.64)
0.80 (0.26, 2.52)	1.03 (0.48, 2.20)	1.03 (0.56, 1.87)	0.23 (0.01, 5.00)	4.49 (1.26, 16.02)	0.86 (0.49, 1.51)	0.88 (0.48, 1.60)	mfa-(w/med+slfm)																																	1.00 (0.61, 1.63)
0.65 (0.17, 2.54)	0.83 (0.29, 2.40)	0.83 (0.32, 2.15)	0.18 (0.01, 4.42)	3.64 (0.84, 15.85)	0.70 (0.28, 1.77)	0.71 (0.27, 1.85)	0.81 (0.29, 2.30)	mfa-(w/med)																																0.72 (0.08, 6.49)
0.90 (0.29, 2.76)	1.15 (0.56, 2.38)	1.15 (0.66, 1.99)	0.25 (0.01, 5.56)	5.04 (1.44, 17.60)	0.97 (0.59, 1.57)	0.99 (0.62, 1.57)	1.12 (0.56, 2.26)	1.38 (0.50, 3.80)	mfa-																									0.94 (0.05, 16.37)					0.83 (0.23, 3.04)	0.53 (0.26, 1.11)
2.31 (0.10, 51.08)	2.95 (0.15, 57.93)	2.95 (0.16, 55.80)	0.65 (0.01, 44.50)	12.91 (0.55, 300.52)	2.48 (0.13, 46.55)	2.53 (0.13, 47.81)	2.87 (0.15, 56.12)	3.54 (0.17, 75.75)	2.56 (0.13, 49.63)	hmcr & ntr										2.77 (1.04, 7.35)																				
4.58 (0.29, 72.02)	5.86 (0.43, 80.42)	5.86 (0.45, 77.05)	1.28 (0.02, 69.26)	25.66 (1.54, 426.33)	4.93 (0.38, 64.21)	5.02 (0.38, 66.03)	5.71 (0.42, 77.84)	7.04 (0.47, 106.34)	5.09 (0.38, 68.76)	1.99 (0.22, 17.94)	hmcr & mfar(w/slfm)		1.07 (0.33, 3.45)																											
7.89 (0.41, 152.04)	10.08 (0.59, 171.42)	10.08 (0.62, 164.91)	2.21 (0.04, 137.64)	44.17 (2.18, 896.57)	8.48 (0.52, 137.31)	8.64 (0.53, 140.93)	9.83 (0.58, 166.02)	12.12 (0.65, 225.78)	8.77 (0.52, 147.29)	3.42 (1.18, 9.91)	1.72 (0.23, 12.70)	hmcr & mfar(w/med)								0.80 (0.57, 1.11)																				
4.89 (0.41, 58.64)	6.25 (0.61, 64.47)	6.25 (0.64, 61.45)	1.37 (0.03, 61.62)	27.37 (2.14, 349.21)	5.25 (0.54, 51.14)	5.35 (0.54, 52.65)	6.09 (0.59, 62.35)	7.51 (0.65, 86.21)	5.43 (0.54, 55.01)	2.12 (0.33, 13.49)	1.07 (0.32, 3.50)	0.62 (0.12, 3.09)	hmcr & mfar	0.53 (0.23, 1.21)																										0.16 (0.02, 1.57)
2.60 (0.19, 35.92)	3.33 (0.28, 39.82)	3.33 (0.29, 38.06)	0.73 (0.01, 36.00)	14.58 (1.00, 213.19)	2.80 (0.25, 31.70)	2.85 (0.25, 32.62)	3.24 (0.27, 38.53)	4.00 (0.30, 52.92)	2.89 (0.25, 34.02)	1.13 (0.22, 5.86)	0.57 (0.13, 2.44)	0.33 (0.08, 1.29)	0.53 (0.23, 1.24)	hmcr & mfa-					1.40 (0.52, 3.77)																					
4.97 (0.25, 98.47)	6.34 (0.36, 111.17)	6.34 (0.38, 106.91)	1.39 (0.02, 88.42)	27.79 (1.33, 580.40)	5.34 (0.32, 89.16)	5.44 (0.32, 91.61)	6.18 (0.36, 107.67)	7.63 (0.40, 145.84)	5.52 (0.32, 95.18)	2.15 (0.69, 6.74)	1.08 (0.14, 8.34)	0.63 (0.32, 1.24)	1.02 (0.19, 5.33)	1.91 (0.46, 7.95)	hmcr & med					1.29 (0.76, 2.18)																				
2.62 (0.10, 70.15)	3.34 (0.14, 80.13)	3.34 (0.14, 77.37)	0.73 (0.01, 58.18)	14.65 (0.52, 411.56)	2.81 (0.12, 64.58)	2.87 (0.12, 66.30)	3.26 (0.14, 77.66)	4.02 (0.15, 104.25)	2.91 (0.12, 68.72)	1.13 (0.19, 6.78)	0.57 (0.05, 6.69)	0.33 (0.07, 1.53)	0.54 (0.06, 4.62)	1.00 (0.14, 7.29)	0.53 (0.11, 2.58)	hmcr & hmnt & exrc				2.44 (0.56, 10.65)																				
6.71 (0.35, 129.70)	8.57 (0.50, 146.26)	8.57 (0.52, 140.61)	1.88 (0.03, 117.31)	37.56 (1.84, 764.82)	7.21 (0.44, 117.25)	7.35 (0.45, 120.49)	8.36 (0.49, 141.65)	10.31 (0.55, 192.04)	7.45 (0.44, 125.21)	2.91 (1.00, 8.50)	1.46 (0.20, 10.85)	0.85 (0.49, 1.48)	1.37 (0.27, 6.88)	2.58 (0.65, 10.17)	1.35 (0.68, 2.70)	2.56 (0.55, 11.95)	hmcr & educ & mfar			0.95 (0.67, 1.36)																				
10.95 (0.43, 275.95)	13.98 (0.62, 314.52)	13.98 (0.64, 303.44)	3.07 (0.04, 232.40)	61.26 (2.32, 1620.34)	11.76 (0.55, 253.23)	11.99 (0.55, 260.02)	13.63 (0.61, 304.78)	16.81 (0.69, 409.82)	12.16 (0.55, 269.63)	4.75 (0.89, 25.26)	2.39 (0.22, 25.77)	1.39 (0.34, 5.60)	2.24 (0.29, 17.56)	4.20 (0.64, 27.51)	2.20 (0.51, 9.46)	4.18 (0.56, 31.00)	1.63 (0.40, 6.64)	hmcr & aids		0.58 (0.15, 2.21)																				
3.66 (0.22, 60.73)	4.67 (0.32, 68.00)	4.67 (0.33, 65.22)	1.02 (0.02, 57.42)	20.47 (1.17, 359.11)	3.93 (0.28, 54.36)	4.00 (0.29, 55.89)	4.55 (0.32, 65.83)	5.62 (0.35, 89.74)	4.06 (0.28, 58.16)	1.59 (0.43, 5.84)	0.80 (0.14, 4.69)	0.46 (0.18, 1.17)	0.75 (0.20, 2.78)	1.40 (0.51, 3.84)	0.74 (0.27, 2.03)	1.40 (0.25, 7.71)	0.54 (0.21, 1.39)	0.33 (0.07, 1.63)	hmcr & ADL & mfar(w/slfm)	1.75 (0.77, 3.98)																				
6.38 (0.34, 120.06)	8.16 (0.49, 135.22)	8.16 (0.51, 129.94)	1.79 (0.03, 109.44)	35.73 (1.80, 708.27)	6.86 (0.43, 108.35)	6.99 (0.44, 111.34)	7.95 (0.48, 130.95)	9.81 (0.54, 177.69)	7.09 (0.43, 115.74)	2.77 (1.02, 7.48)	1.39 (0.20, 9.91)	0.81 (0.55, 1.18)	1.31 (0.27, 6.22)	2.45 (0.66, 9.11)	1.29 (0.73, 2.25)	2.44 (0.55, 10.77)	0.95 (0.64, 1.42)	0.58 (0.15, 2.24)	1.75 (0.75, 4.06)	hmcr																				
																					exrc & psyc	exrc & mfar(w/med+slfm)	exrc & mfa-(w/med)	exrc	educ & rsk-mfa-	educ & mfar(w/med+slfm)	educ & mfar(w/med)	educ & mfa-	educ & exrc & mfar(w/slfm)	educ & exrc & mfar(w/med+slfm)	educ	cgn & ntr & exrc	cgn & med & ntr & exrc	aids	ADL&aids&ed&ex&mf(w/med+slfm)	ADL & ntr & exrc	ADL & exrc	ADL & aids & exrc	ADL	ac

wlfr	vchr	rsk-mfa-	ntr & exrc	mntr-mfa-	mfar(w/ med)	mfar	mfa-(w/med +slfm)	mfa-(w/med)	mfa-	hmcr & ntr	hmcr & mfar(w/ slfm)	hmcr & mfar(w/ med)	hmcr & mfar	hmcr & mfa-	hmcr & med	hmcr & hmnt & exrc	hmcr & educ & mfar	hmcr & aids	hmcr & ADL & mfar(w/ slfm)	hmcr																		
0.20 (0.02, 2.25)	0.25 (0.03, 2.47)	0.25 (0.03, 2.35)	0.06 (0.00, 2.41)	1.11 (0.09, 13.44)	0.21 (0.02, 1.96)	0.22 (0.02, 2.01)	0.25 (0.03, 2.39)	0.30 (0.03, 3.31)	0.22 (0.02, 2.11)	0.09 (0.00, 3.36)	0.04 (0.00, 1.27)	0.03 (0.00, 0.87)	0.04 (0.00, 0.96)	0.08 (0.00, 2.01)	0.04 (0.00, 1.42)	0.08 (0.00, 3.48)	0.03 (0.00, 1.03)	0.02 (0.00, 0.79)	0.05 (0.00, 1.67)	0.03 (0.00, 1.06)	exrc & psyc																	4.06 (0.45, 36.83)
0.66 (0.17, 2.55)	0.84 (0.29, 2.42)	0.84 (0.33, 2.16)	0.18 (0.01, 4.45)	3.67 (0.85, 15.94)	0.71 (0.28, 1.77)	0.72 (0.28, 1.85)	0.82 (0.29, 2.31)	1.01 (0.28, 3.61)	0.73 (0.26, 2.01)	0.28 (0.01, 6.08)	0.14 (0.01, 2.16)	0.08 (0.00, 1.54)	0.13 (0.01, 1.54)	0.25 (0.02, 3.33)	0.13 (0.01, 2.52)	0.25 (0.01, 6.50)	0.10 (0.01, 1.82)	0.06 (0.00, 1.46)	0.18 (0.01, 2.86)	0.10 (0.01, 1.86)	3.32 (0.30, 36.21)	exrc & mfar(w/ med+slfm)														1.22 (0.51, 2.95)
0.53 (0.07, 4.24)	0.68 (0.10, 4.51)	0.68 (0.11, 4.25)	0.15 (0.00, 5.20)	2.98 (0.35, 25.54)	0.57 (0.09, 3.53)	0.58 (0.09, 3.64)	0.66 (0.10, 4.36)	0.82 (0.11, 6.18)	0.59 (0.09, 3.83)	0.23 (0.01, 7.20)	0.12 (0.01, 2.67)	0.07 (0.00, 1.86)	0.11 (0.01, 1.98)	0.20 (0.01, 4.19)	0.11 (0.00, 3.03)	0.20 (0.01, 7.54)	0.08 (0.00, 2.19)	0.05 (0.00, 1.71)	0.15 (0.01, 3.51)	0.08 (0.00, 2.25)	2.69 (0.15, 46.96)	0.81 (0.11, 6.12)	exrc & mfa-(w/med)													1.51 (0.25, 9.11)
4.84 (0.45, 51.51)	6.18 (0.68, 56.18)	6.19 (0.72, 53.39)	1.36 (0.03, 56.48)	27.09 (2.39, 307.69)	5.20 (0.61, 44.41)	5.30 (0.61, 45.74)	6.03 (0.67, 54.30)	7.43 (0.73, 75.56)	5.38 (0.60, 47.88)	2.10 (0.06, 78.59)	1.06 (0.04, 29.61)	0.61 (0.02, 20.39)	0.99 (0.04, 22.29)	1.86 (0.07, 46.84)	0.97 (0.03, 33.22)	1.85 (0.04, 81.62)	0.72 (0.02, 24.06)	0.44 (0.01, 18.51)	1.32 (0.05, 38.87)	0.76 (0.02, 24.70)	24.51 (1.13, 530.54)	7.38 (0.73, 74.86)	9.09 (0.55, 149.36)	exrc												0.17 (0.02, 1.39)
0.80 (0.24, 2.69)	1.02 (0.43, 2.43)	1.03 (0.50, 2.11)	0.22 (0.01, 5.13)	4.49 (1.18, 17.03)	0.86 (0.43, 1.71)	0.88 (0.43, 1.80)	1.00 (0.43, 2.31)	1.23 (0.40, 3.77)	0.89 (0.40, 2.00)	0.35 (0.02, 6.98)	0.18 (0.01, 2.46)	0.10 (0.01, 1.77)	0.16 (0.02, 1.74)	0.31 (0.03, 3.78)	0.16 (0.01, 2.89)	0.31 (0.01, 7.49)	0.12 (0.01, 2.08)	0.07 (0.00, 1.68)	0.22 (0.01, 3.27)	0.13 (0.01, 2.13)	4.06 (0.40, 40.85)	1.22 (0.40, 3.73)	1.51 (0.22, 10.33)	0.17 (0.02, 1.55)	educ & rsk-mfa-												1.00 (0.53, 1.88)
0.70 (0.22, 2.23)	0.89 (0.40, 1.97)	0.89 (0.47, 1.68)	0.20 (0.01, 4.38)	3.91 (1.08, 14.17)	0.75 (0.41, 1.36)	0.76 (0.41, 1.44)	0.87 (0.40, 1.87)	1.07 (0.37, 3.11)	0.78 (0.37, 1.62)	0.30 (0.02, 5.96)	0.15 (0.01, 2.09)	0.09 (0.01, 1.50)	0.14 (0.01, 1.48)	0.27 (0.02, 3.21)	0.14 (0.01, 2.47)	0.27 (0.01, 6.40)	0.10 (0.01, 1.78)	0.06 (0.00, 1.44)	0.19 (0.01, 2.78)	0.11 (0.01, 1.82)	3.54 (0.36, 34.66)	1.06 (0.37, 3.07)	1.31 (0.20, 8.72)	0.14 (0.02, 1.31)	0.87 (0.37, 2.07)	educ & mfar(w/ med+slfm)											1.14 (0.66, 1.97)
0.73 (0.24, 2.17)	0.93 (0.46, 1.85)	0.93 (0.56, 1.54)	0.20 (0.01, 4.45)	4.07 (1.19, 13.92)	0.78 (0.49, 1.23)	0.80 (0.48, 1.32)	0.90 (0.47, 1.76)	1.12 (0.41, 3.01)	0.81 (0.43, 1.50)	0.32 (0.02, 6.05)	0.16 (0.01, 2.12)	0.09 (0.01, 1.53)	0.15 (0.01, 1.49)	0.28 (0.02, 3.25)	0.15 (0.01, 2.50)	0.28 (0.01, 6.51)	0.11 (0.01, 1.80)	0.07 (0.00, 1.46)	0.20 (0.01, 2.82)	0.11 (0.01, 1.84)	3.68 (0.39, 34.92)	1.11 (0.41, 2.98)	1.36 (0.21, 8.73)	0.15 (0.02, 1.32)	0.91 (0.42, 1.97)	1.04 (0.52, 2.09)	educ & mfar(w/ med)										1.11 (0.76, 1.62)
0.61 (0.08, 4.50)	0.78 (0.13, 4.76)	0.78 (0.14, 4.47)	0.17 (0.01, 5.71)	3.41 (0.43, 27.22)	0.65 (0.12, 3.71)	0.67 (0.12, 3.83)	0.76 (0.13, 4.59)	0.94 (0.13, 6.55)	0.68 (0.11, 4.04)	0.26 (0.01, 7.89)	0.13 (0.01, 2.91)	0.08 (0.00, 2.03)	0.12 (0.01, 2.15)	0.23 (0.01, 4.56)	0.12 (0.00, 3.31)	0.23 (0.01, 8.27)	0.09 (0.00, 2.39)	0.06 (0.00, 1.87)	0.17 (0.01, 3.83)	0.10 (0.00, 2.45)	3.08 (0.19, 50.95)	0.93 (0.13, 6.49)	1.14 (0.09, 13.92)	0.13 (0.01, 1.96)	0.76 (0.12, 4.81)	0.87 (0.14, 5.34)	0.84 (0.14, 4.93)	educ & mfa-									1.32 (0.24, 7.31)
0.67 (0.13, 3.62)	0.86 (0.20, 3.68)	0.86 (0.22, 3.40)	0.19 (0.01, 5.32)	3.77 (0.64, 22.20)	0.72 (0.19, 2.81)	0.74 (0.19, 2.91)	0.84 (0.20, 3.54)	1.04 (0.21, 5.21)	0.75 (0.18, 3.10)	0.29 (0.01, 7.31)	0.15 (0.01, 2.65)	0.09 (0.00, 1.87)	0.14 (0.01, 1.92)	0.26 (0.02, 4.11)	0.14 (0.01, 3.05)	0.26 (0.01, 7.74)	0.10 (0.00, 2.20)	0.06 (0.00, 1.74)	0.18 (0.01, 3.50)	0.11 (0.00, 2.26)	3.41 (0.26, 45.36)	1.03 (0.20, 5.16)	1.27 (0.13, 12.04)	0.14 (0.01, 1.73)	0.84 (0.19, 3.74)	0.97 (0.23, 4.13)	0.93 (0.23, 3.77)	1.11 (0.12, 9.83)	educ & exrc & mfar(w/ slfm)								1.19 (0.32, 4.48)
1.64 (0.12, 22.71)	2.09 (0.17, 25.19)	2.09 (0.18, 24.08)	0.46 (0.01, 22.73)	9.17 (0.62, 134.81)	1.76 (0.15, 20.06)	1.79 (0.16, 20.63)	2.04 (0.17, 24.37)	2.52 (0.19, 33.47)	1.82 (0.15, 21.52)	0.71 (0.02, 31.79)	0.36 (0.01, 12.15)	0.21 (0.01, 8.29)	0.34 (0.01, 9.27)	0.63 (0.02, 19.34)	0.33 (0.01, 13.49)	0.63 (0.01, 32.77)	0.24 (0.01, 9.78)	0.15 (0.00, 7.45)	0.45 (0.01, 15.91)	0.26 (0.01, 10.06)	8.30 (0.31, 221.05)	2.50 (0.19, 33.17)	3.08 (0.15, 63.43)	0.34 (0.01, 8.57)	2.04 (0.17, 25.20)	2.35 (0.19, 28.27)	2.26 (0.19, 26.40)	2.69 (0.14, 52.74)	2.43 (0.15, 38.79)	educ & exrc & mfar(w/ med+slfm)							0.49 (0.04, 5.49)
0.57 (0.03, 11.19)	0.73 (0.04, 12.62)	0.73 (0.04, 12.14)	0.16 (0.00, 10.06)	3.18 (0.15, 65.93)	0.61 (0.04, 10.12)	0.62 (0.04, 10.40)	0.71 (0.04, 12.23)	0.87 (0.05, 16.56)	0.63 (0.04, 10.81)	0.25 (0.00, 14.16)	0.12 (0.00, 5.51)	0.07 (0.00, 3.72)	0.12 (0.00, 4.27)	0.22 (0.01, 8.84)	0.11 (0.00, 6.05)	0.22 (0.00, 14.46)	0.08 (0.00, 4.39)	0.05 (0.00, 3.30)	0.16 (0.00, 7.20)	0.09 (0.00, 4.52)	2.88 (0.08, 102.14)	0.87 (0.05, 16.42)	1.07 (0.04, 29.96)	0.12 (0.00, 3.98)	0.71 (0.04, 12.59)	0.81 (0.05, 14.16)	0.78 (0.05, 13.27)	0.93 (0.03, 25.04)	0.84 (0.04, 18.80)	0.35 (0.01, 14.09)	educ						1.41 (0.09, 23.10)
2.51 (0.08, 74.26)	3.21 (0.12, 85.11)	3.21 (0.13, 82.26)	0.70 (0.01, 60.13)	14.05 (0.45, 435.06)	2.70 (0.11, 68.68)	2.75 (0.11, 70.49)	3.13 (0.12, 82.50)	3.86 (0.13, 110.46)	2.79 (0.11, 73.02)	1.09 (0.01, 85.15)	0.55 (0.01, 33.79)	0.32 (0.00, 22.55)	0.51 (0.01, 26.59)	0.96 (0.02, 54.58)	0.51 (0.01, 36.58)	0.96 (0.01, 86.08)	0.37 (0.01, 26.59)	0.23 (0.00, 19.69)	0.69 (0.01, 43.97)	0.39 (0.01, 27.42)	12.71 (0.25, 638.04)	3.83 (0.13, 109.49)	4.72 (0.12, 191.36)	0.52 (0.01, 24.94)	3.13 (0.12, 84.63)	3.59 (0.14, 95.48)	3.46 (0.13, 89.79)	4.12 (0.11, 160.62)	3.72 (0.11, 123.01)	1.53 (0.03, 87.01)	4.42 (0.06, 317.95)	cgn & ntr & exrc						0.32 (0.01, 8.05)
1.64 (0.39, 6.94)	2.10 (0.66, 6.72)	2.10 (0.73, 6.08)	0.46 (0.02, 11.57)	9.20 (1.96, 43.15)	1.77 (0.62, 5.00)	1.80 (0.62, 5.21)	2.05 (0.65, 6.45)	2.53 (0.65, 9.88)	1.83 (0.59, 5.62)	0.71 (0.03, 15.82)	0.36 (0.02, 5.65)	0.21 (0.01, 4.02)	0.34 (0.03, 4.04)	0.63 (0.05, 8.72)	0.33 (0.02, 6.58)	0.63 (0.02, 16.87)	0.25 (0.01, 4.75)	0.15 (0.01, 3.79)	0.45 (0.03, 7.48)	0.26 (0.01, 4.85)	8.33 (0.73, 95.22)	2.51 (0.64, 9.78)	3.09 (0.39, 24.67)	0.34 (0.03, 3.62)	2.05 (0.61, 6.91)	2.35 (0.73, 7.55)	2.26 (0.75, 6.81)	2.70 (0.36, 20.04)	2.44 (0.45, 13.14)	1.00 (0.07, 13.93)	2.89 (0.15, 57.06)	0.66 (0.02, 19.41)	cgn & med & ntr & exrc					0.49 (0.18, 1.33)
0.84 (0.04, 18.30)	1.08 (0.06, 20.74)	1.08 (0.06, 19.96)	0.24 (0.00, 16.04)	4.72 (0.21, 107.72)	0.91 (0.05, 16.60)	0.92 (0.05, 16.85)	1.05 (0.05, 20.09)	1.30 (0.06, 27.07)	0.94 (0.05, 16.47)	0.37 (0.01, 22.60)	0.18 (0.00, 8.84)	0.11 (0.00, 5.97)	0.17 (0.00, 6.87)	0.32 (0.01, 14.19)	0.17 (0.00, 9.66)	0.32 (0.00, 23.02)	0.13 (0.00, 7.02)	0.08 (0.00, 5.25)	0.23 (0.00, 11.53)	0.13 (0.00, 7.23)	4.27 (0.11, 164.55)	1.29 (0.06, 26.90)	1.59 (0.05, 48.55)	0.17 (0.00, 6.41)	1.05 (0.05, 20.67)	1.21 (0.06, 23.29)	1.16 (0.06, 21.81)	1.39 (0.05, 40.61)	1.25 (0.05, 30.65)	0.51 (0.01, 22.63)	1.49 (0.03, 83.97)	0.34 (0.00, 25.91)	0.51 (0.02, 11.15)	aids					
0.10 (0.01, 1.00)	0.12 (0.01, 1.09)	0.12 (0.01, 1.04)	0.03 (0.00, 1.11)	0.54 (0.05, 6.00)	0.10 (0.01, 0.86)	0.11 (0.01, 0.89)	0.12 (0.01, 1.06)	0.15 (0.02, 1.47)	0.11 (0.01, 0.93)	0.04 (0.00, 1.55)	0.02 (0.00, 0.58)	0.01 (0.00, 0.40)	0.02 (0.00, 0.44)	0.04 (0.00, 0.92)	0.02 (0.00, 0.65)	0.04 (0.00, 1.61)	0.01 (0.00, 0.47)	0.01 (0.00, 0.36)	0.03 (0.00, 0.76)	0.02 (0.00, 0.49)	0.49 (0.02, 10.41)	0.15 (0.02, 1.46)	0.18 (0.01, 2.92)	0.02 (0.00, 0.40)	0.12 (0.01, 1.10)	0.14 (0.02, 1.23)	0.13 (0.02, 1.14)	0.16 (0.01, 2.42)	0.14 (0.01, 1.74)	0.06 (0.00, 1.47)	0.17 (0.01, 5.68)	0.04 (0.00, 1.83)	0.06 (0.01, 0.61)	0.12 (0.00, 4.15)	ADL&aids&ed&ex&mf(w/med+slfm)					8.25 (1.02, 66.86)
1.68 (0.37, 7.58)	2.14 (0.62, 7.45)	2.14 (0.68, 6.79)	0.47 (0.02, 12.17)	9.39 (1.88, 46.89)	1.80 (0.58, 5.59)	1.84 (0.58, 5.81)	2.09 (0.61, 7.15)	2.58 (0.61, 10.82)	1.86 (0.56, 6.25)	0.73 (0.03, 16.66)	0.37 (0.02, 5.97)	0.21 (0.01, 4.24)	0.34 (0.03, 4.29)	0.64 (0.04, 9.24)	0.34 (0.02, 6.94)	0.64 (0.02, 17.73)	0.25 (0.01, 5.00)	0.15 (0.01, 3.99)	0.46 (0.03, 7.91)	0.26 (0.01, 5.12)	8.49 (0.71, 101.15)	2.56 (0.61, 10.71)	3.15 (0.38, 26.39)	0.35 (0.03, 3.85)	2.09 (0.57, 7.63)	2.40 (0.69, 8.37)	2.31 (0.70, 7.58)	2.75 (0.35, 21.47)	2.49 (0.43, 14.21)	1.02 (0.07, 14.76)	2.95 (0.14, 60.17)	0.67 (0.02, 20.39)	1.02 (0.22, 4.63)	1.99 (0.09, 44.60)	17.24 (1.60, 186.01)	ADL & ntr & exrc					0.48 (0.16, 1.44)
0.52 (0.10, 2.75)	0.67 (0.16, 2.78)	0.67 (0.17, 2.56)	0.15 (0.01, 4.08)	2.93 (0.51, 16.86)	0.56 (0.15, 2.12)	0.57 (0.15, 2.20)	0.65 (0.16, 2.67)	0.80 (0.16, 3.95)	0.58 (0.14, 2.34)	0.23 (0.01, 5.60)	0.11 (0.01, 2.03)	0.07 (0.00, 1.43)	0.11 (0.01, 1.47)	0.20 (0.01, 3.15)	0.11 (0.00, 2.34)	0.20 (0.01, 5.94)	0.08 (0.00, 1.69)	0.05 (0.00, 1.34)	0.14 (0.01, 2.68)	0.08 (0.00, 1.73)	2.65 (0.20, 34.68)	0.80 (0.16, 3.91)	0.98 (0.11, 9.18)	0.11 (0.01, 1.32)	0.65 (0.15, 2.83)	0.75 (0.18, 3.12)	0.72 (0.18, 2.85)	0.86 (0.10, 7.50)	0.78 (0.12, 5.06)	0.32 (0.02, 5.03)	0.92 (0.04, 20.29)	0.21 (0.01, 6.81)	0.32 (0.06, 1.68)	0.62 (0.03, 15.00)	5.38 (0.45, 64.01)	0.31 (0.06, 1.75)	ADL & exrc				1.53 (0.42, 5.62)
5.17 (0.83, 32.34)	6.61 (1.30, 33.51)	6.61 (1.40, 31.24)	1.45 (0.05, 44.16)	28.96 (4.26, 196.69)	5.56 (1.19, 25.88)	5.67 (1.20, 26.77)	6.44 (1.29, 32.29)	7.95 (1.35, 46.78)	5.75 (1.17, 28.35)	2.24 (0.08, 60.84)	1.13 (0.06, 22.22)	0.66 (0.03, 15.60)	1.06 (0.07, 16.26)	1.99 (0.11, 34.68)	1.04 (0.04, 25.47)	1.98 (0.06, 64.15)	0.77 (0.03, 18.40)	0.47 (0.02, 14.48)	1.41 (0.07, 29.32)	0.81 (0.03, 18.85)	26.19 (1.78, 384.82)	7.88 (1.34, 46.33)	9.72 (0.91, 103.59)	1.07 (0.08, 14.74)	6.45 (1.22, 33.96)	7.41 (1.46, 37.63)	7.12 (1.47, 34.58)	8.50 (0.85, 84.92)	7.67 (1.01, 58.42)	3.16 (0.18, 55.36)	9.10 (0.38, 221.01)	2.06 (0.06, 73.43)	3.15 (0.50, 19.72)	6.13 (0.23, 162.98)	53.18 (3.96, 713.37)	3.09 (0.47, 20.41)	9.89 (1.32, 73.98)	ADL & aids & exrc		0.16 (0.03, 0.70)
0.78 (0.21, 2.93)	0.99 (0.36, 2.76)	0.99 (0.40, 2.45)	0.22 (0.01, 5.21)	4.35 (1.03, 18.38)	0.83 (0.35, 2.00)	0.85 (0.35, 2.06)	0.97 (0.36, 2.64)	1.19 (0.34, 4.13)	0.86 (0.36, 2.08)	0.34 (0.02, 7.11)	0.17 (0.01, 2.52)	0.10 (0.01, 1.80)	0.16 (0.01, 1.79)	0.30 (0.02, 3.88)	0.16 (0.01, 2.95)	0.30 (0.01, 7.60)	0.12 (0.01, 2.13)	0.07 (0.00, 1.71)	0.21 (0.01, 3.34)	0.12 (0.01, 2.17)	3.93 (0.37, 42.19)	1.18 (0.34, 4.10)	1.46 (0.20, 10.80)	0.16 (0.02, 1.60)	0.97 (0.33, 2.85)	1.11 (0.40, 3.10)	1.07 (0.41, 2.76)	1.28 (0.19, 8.75)	1.15 (0.23, 5.65)	0.47 (0.04, 6.20)	1.37 (0.07, 25.59)	0.31 (0.01, 8.76)	0.47 (0.12, 1.79)	0.92 (0.05, 18.46)	7.99 (0.83, 77.23)	0.46 (0.11, 1.89)	1.49 (0.31, 7.12)	0.15 (0.03, 0.86)	ADL		1.01 (0.35, 2.92)
0.80 (0.29, 2.22)	1.02 (0.59, 1.79)	1.03 (0.76, 1.37)	0.22 (0.01, 4.78)	4.49 (1.41, 14.31)	0.86 (0.71, 1.05)	0.88 (0.66, 1.18)	1.00 (0.59, 1.68)	1.23 (0.50, 3.04)	0.89 (0.56, 1.43)	0.35 (0.02, 6.49)	0.18 (0.01, 2.26)	0.10 (0.01, 1.64)	0.16 (0.02, 1.58)	0.31 (0.03, 3.46)	0.16 (0.01, 2.68)	0.31 (0.01, 7.00)	0.12 (0.01, 1.93)	0.07 (0.00, 1.57)	0.22 (0.02, 3.01)	0.13 (0.01, 1.97)	4.06 (0.44, 37.12)	1.22 (0.50, 3.01)	1.51 (0.25, 9.20)	0.17 (0.02, 1.40)	1.00 (0.52, 1.93)	1.15 (0.66, 2.01)	1.10 (0.73, 1.67)	1.32 (0.23, 7.39)	1.19 (0.31, 4.54)	0.49 (0.04, 5.53)	1.41 (0.09, 23.24)	0.32 (0.01, 8.09)	0.49 (0.18, 1.35)	0.95 (0.05, 17.35)	8.25 (1.01, 67.42)	0.48 (0.16, 1.46)	1.53 (0.41, 5.70)	0.16 (0.03, 0.71)	1.03 (0.44, 2.43)	ac

Please note: the results of mortality: medium-term network are too large to fit on one page. Please refer to Supplementary Material 8: NMA estimate and rank tables: sheet mort-t2-all.

Table 79 - Intervention rankings for mortality: medium-term network

Treatment	SUCRA	Pr(Best)	Mean Rank	LCI Rank	UCI Rank
hmcr & aids	89.7	29.2	5.1	1	27
hmcr & mfar(w/med)	87.5	7.5	6	1	27
hmcr & educ & mfar	83.2	2.2	7.7	1	30
hmcr	82.1	0.4	8.1	2	29
ADL & aids & exrc	81.1	8.4	8.6	1	19
exrc	78.5	12.2	9.6	1	34
hmcr & mfar	78.5	1.2	9.6	2	28
hmcr & med	75.6	0.5	10.8	2	34
hmcr & mfar(w/slfm)	75.4	4.3	10.8	1	34
ntr & exrc	69.9	14.1	13	1	39
hmcr & ADL & mfar(w/slfm)	69.8	0.1	13.1	5	35
cgn & ntr & exrc	63.5	12.1	15.6	1	40
hmcr & mfa-	62.8	0	15.9	7	37
ADL & ntr & exrc	62.1	0.2	16.1	4	33
cgn & med & ntr & exrc	61.7	0	16.3	4	32
hmcr & hmnt & exrc	60.5	0.9	16.8	2	40
educ & exrc & mfar(w/med+slfm)	57.7	3.1	17.9	1	40
hmcr & ntr	57.6	0.2	17.9	6	39
mfar(w/med)	47.4	0	22.1	13	29
wlfr	45.7	0	22.7	7	37
mfar	45.3	0	22.9	12	31
mfa-	44.4	0	23.2	11	34
aids	41	2.2	24.6	2	41
mfa-(w/med+slfm)	38.6	0	25.5	14	35
ADL	37.8	0	25.9	12	37
educ & rsk-mfa-	37.8	0	25.9	11	36
vchr	37.7	0	25.9	14	36
ac	37.5	0	26	18	31
rsk-mfa-	36.5	0	26.4	16	34
educ	34.6	1.1	27.2	3	41
educ & exrc & mfar(w/slfm)	33	0.1	27.8	8	39
educ & mfar(w/med)	32.9	0	27.8	17	36
educ & mfar(w/med+slfm)	31.6	0	28.4	16	36
educ & mfa-	31.4	0	28.4	7	40
exrc & mfar(w/med+slfm)	31.1	0	28.6	11	38
mfa-(w/med)	30.5	0	28.8	14	38
exrc & mfa-(w/med)	28.2	0	29.7	8	41
ADL & exrc	25.2	0	30.9	11	40
exrc & psyc	12.7	0	35.9	15	41
mntr-mfa-	6.2	0	38.5	32	41
ADL&aids&ed&ex&mf(w/med+slfm)	5.4	0	38.9	23	41

SUCRA values (0–100) and mean ranks are presented, based on 1000 simulations. Higher SUCRAs and lower mean ranks indicate better performing interventions. Pr(Best) gives the probability of each specific intervention being ranked best intervention, based on 1000 simulations.



Figure 47 - Pairwise meta-analysis for mortality: medium-term network (pooling comparisons with greater than one study reporting results

References

1. Challis D, Clarkson P, Williamson J, Hughes J, Venables D, Burns A*, et al.* The value of specialist clinical assessment of older people prior to entry to care homes. *Age Ageing* 2004;**33**:25-34. https://doi.org/10.1093/ageing/afh007

2. Imhof L, Naef R, Wallhagen MI, Schwarz J, Mahrer-Imhof R. Effects of an advanced practice nurse in-home health consultation program for community-dwelling persons aged 80 and older. *J Am Geriatr Soc* 2012;**60**:2223-31. https://doi.org/10.1111/jgs.12026

3. Kukkonen-Harjula K, Karmeniemi P, Suikkanen S, Kaaria S, Sipila S, Pitkala K*, et al.* Long-term home-based physiotherapy for older people with signs of frailty-RCT (NCT02305433) [P-229]. *Eur Geriatr Med* 2017;**8**:S105. https://doi.org/10.1016/S1878-7649(17)30179-1

4. Liddle J, March L, Carfrae B, Finnegan T, Druce J, Schwarz J*, et al.* Can occupational therapy intervention play a part in maintaining independence and quality of life in older people? A randomised controlled trial. *Aust N Z J Public Health* 1996;**20**:574-8. https://doi.org/10.1111/j.1467-842x.1996.tb01068.x

5. Metzelthin SF, Van Rossum E, De Witte LP, Ambergen AW, Hobma SO, Sipers W*, et al.* Effectiveness of interdisciplinary primary care approach to reduce disability in community dwelling frail older people: Cluster randomised controlled trial. *BMJ* 2013;**347**:f5264. https://doi.org/10.1136/bmj.f5264

6. Suijker JJ, van Rijn M, Buurman BM, Ter Riet G, Moll van Charante EP, de Rooij SE. Effects of nurse-led multifactorial care to prevent disability in community-living older people: Cluster randomized trial. *PLoS One* 2016;**11**:e0158714. https://doi.org/10.1371/journal.pone.0158714

7. Szanton SL, Thorpe RJ, Boyd C, Tanner EK, Leff B, Agree E*, et al.* Community aging in place, advancing better living for elders: a bio-behavioral-environmental intervention to improve function and health-related quality of life in disabled older adults. *J Am Geriatr Soc* 2011;**59**:2314-20. https://doi.org/10.1111/j.1532-5415.2011.03698.x

8. Wong AKC, Wong FKY, Chang K. Effectiveness of a community-based self-care promoting program for community-dwelling older adults: A randomized controlled trial. *Age Ageing* 2019;**48**:852-8. https://doi.org/10.1093/ageing/afz095

9. Blom J, den Elzen W, van Houwelingen AH, Heijmans M, Stijnen T, Van den Hout W*, et al.* Effectiveness and cost-effectiveness of a proactive, goal-oriented, integrated care model in general practice for older people. A cluster randomised controlled trial: Integrated Systematic Care for older People--the ISCOPE study. *Age Ageing* 2016;**45**:30-41. https://doi.org/10.1093/ageing/afv174

10. Dalby DM, Sellors JW, Fraser FD, Fraser C, van Ineveld C, Howard M. Effect of preventive home visits by a nurse on the outcomes of frail elderly people in the community: a randomized controlled trial. *CMAJ* 2000;**162**:497-500.

11. Fabacher D, Josephson K, Pietruszka F, Linderborn K, Morley JE, Rubenstein LZ. An in-home preventive assessment program for independent older adults: a randomized controlled trial. *J Am Geriatr Soc* 1994;**42**:630-8. https://doi.org/10.1111/j.1532-5415.1994.tb06862.x

12. Hall N, De Beck P, Johnson D, Mackinnon K, Gutman G, Glick N. Randomized trial of a health promotion program for frail elders. *Can J Aging* 1992;**11**:72-91.

13. Harari D, Iliffe S, Kharicha K, Egger M, Gillmann G, von Renteln-Kruse W*, et al.* Promotion of health in older people: a randomised controlled trial of health risk appraisal in British general practice. *Age Ageing* 2008;**37**:565-71. https://doi.org/10.1093/ageing/afn150

14. Hay WI, van Ineveld C, Browne G, Roberts J, Bell B, Mills M*, et al.* Prospective care of elderly patients in family practice. Is screening effective? *Can Fam Physician* 1998;**44**:2677-87.

15. Hebert R, Robichaud L, Roy PM, Bravo G, Voyer L. Efficacy of a nurse-led multidimensional preventive programme for older people at risk of functional decline. A randomized controlled trial. *Age Ageing* 2001;**30**:147-53. https://doi.org/10.1093/ageing/30.2.147

16. Henderson MJ. *In-home preventive health assessment and telephone case management for over 75s living alone in independent living units: A cluster randomized controlled trial* [PhD thesis]. Queensland: Queensland University of Technology; 2005.

17. Kerse N, McLean C, Moyes SA, Peri K, Ng T, Wilkinson-Meyers L*, et al.* The cluster-randomized BRIGHT trial: Proactive case finding for community-dwelling older adults. *Ann Fam Med* 2014;**12**:514-24. https://doi.org/10.1370/afm.1696

18. Kono A, Kai I, Sakato C, Harker JO, Rubenstein LZ. Effect of preventive home visits for ambulatory housebound elders in Japan: a pilot study. *Aging Clin Exp Res* 2004;**16**:293-9. https://doi.org/10.1007/BF03324554

19. Kono A, Izumi K, Yoshiyuki N, Kanaya Y, Rubenstein LZ. Effects of an updated preventive home visit program based on a systematic structured assessment of care needs for ambulatory frail older adults in Japan: A randomized controlled trial. *J Gerontol A Biol Sci Med Sci* 2016;**71**:1631-7. https://doi.org/10.1093/gerona/glw068

20. Monteserin Nadal R, Altimir Losada S, Brotons Cuixart C, Padros Selma J, Santaeugenia Gonzalez S, Moral Pelaez I*, et al.* Randomized clinical trial on the efficacy of global geriatric assessment in primary care. [Spanish]. *Rev Esp Geriatr Gerontol* 2008;**43**:5-12. https://doi.org/10.1016/s0211-139x(08)71144-2

21. Newbury JW, Marley JE, Beilby JJ. A randomised controlled trial of the outcome of health assessment of people aged 75 years and over. *Med J Aust* 2001;**175**:104-7. https://doi.org/10.5694/j.1326-5377.2001.tb143541.x

22. Newcomer R, Maravilla V, Faculjak P, Graves MT. Outcomes of preventive case management among high-risk elderly in three medical groups: a randomized clinical trial. *Eval Health Prof* 2004;**27**:323-48. https://doi.org/10.1177/0163278704270011

23. Ploeg J, Brazil K, Hutchison B, Kaczorowski J, Dalby DM, Goldsmith CH*, et al.* Effect of preventive primary care outreach on health related quality of life among older adults at risk of functional decline: randomised controlled trial. *BMJ* 2010;**340**:c1480. https://doi.org/10.1136/bmj.c1480

24. Romera-Liebana L, Orfila F, Segura JM, Real J, Fabra ML, Möller M*, et al.* Effects of a primary care-based multifactorial intervention on physical and cognitive function in frail, elderly individuals: A randomized controlled trial. *J Gerontol A Biol Sci Med Sci* 2018;**73**:1688-74. https://doi.org/10.1093/gerona/glx259

25. Shapiro A, Taylor M. Effects of a community-based early intervention program on the subjective well-being, institutionalization, and mortality of low-income elders. *Gerontologist* 2002;**42**:334-41. https://doi.org/10.1093/geront/42.3.334

26. van Hout HP, Jansen AP, van Marwijk HW, Pronk M, Frijters DF, Nijpels G. Prevention of adverse health trajectories in a vulnerable elderly population through nurse home visits: a randomized controlled trial [ISRCTN05358495]. *J Gerontol A Biol Sci Med Sci* 2010;**65**:734-42. https://doi.org/10.1093/gerona/glq037

27. Carpenter GI, Demopoulos GR. Screening the elderly in the community: controlled trial of dependency surveillance using a questionnaire administered by volunteers. *BMJ* 1990;**300**:1253-6. https://doi.org/10.1136/bmj.300.6734.1253

28. Fischer G, Sandholzer H, Perschke-Hartmann C. *Final report of the scientific support of "Getting Healthy Elderly (GÄW)". A prevention project of the AOK Lower Saxony.)[German] (Abschlussbericht der wissenschaftlichen Begleitung von "Gesund Älter Werden (GÄW)")*. unpublished: AOK Niedersachsen; 2009.

29. Ford AB, Katz S, Downs TD, Adams M. Results of long-term home nursing: the influence of disability. *J Chronic Dis* 1971;**24**:591-6. https://doi.org/10.1016/0021-9681(71)90047-6

30. Stuck AE, Aronow HU, Steiner A, Alessi CA, Bula CJ, Gold MN*, et al.* A trial of annual in-home comprehensive geriatric assessments for elderly people living in the community. *N Engl J Med* 1995;**333**:1184-9. https://doi.org/10.1056/NEJM199511023331805

31. Stuck AE, Moser A, Morf U, Wirz U, Wyser J, Gillmann G*, et al.* Effect of health risk assessment and counselling on health behaviour and survival in older people: a pragmatic randomised trial. *PLoS Med* 2015;**12**:e1001889. https://doi.org/10.1371/journal.pmed.1001889

32. Tomita MR, Mann WC, Stanton K, Tomita AD, Sundar V. Use of currently available smart home technology by frail elders: process and outcomes. *Top Geriatr Rehabil* 2007;**23**. https://doi.org/10.1097/00013614-200701000-00005

33. Tulloch AJ, Moore V. A randomized controlled trial of geriatric screening and surveillance in general practice. *J R Coll Gen Pract* 1979;**29**:733-40.

34. Fernandez-Barres S, Garcia-Barco M, Basora J, Martinez T, Pedret R, Arija V*, et al.* The efficacy of a nutrition education intervention to prevent risk of malnutrition for dependent elderly patients receiving Home Care: A randomized controlled trial. *Int J Nurs Stud* 2017;**70**:131-41. https://doi.org/10.1016/j.ijnurstu.2017.02.020

35. King AII, Parsons M, Robinson E, Jorgensen D. Assessing the impact of a restorative home care service in New Zealand: A cluster randomised controlled trial. *Health Soc Care Community* 2012;**20**:365-74. https://doi.org/10.1111/j.1365-2524.2011.01039.x

36. Parsons M, Senior H, Kerse N, Chen MH, Jacobs S, Anderson C. Randomised trial of restorative home care for frail older people in New Zealand. *Nurs Older People* 2017;**29**:27-33. https://doi.org/10.7748/nop.2017.e897

37. Rooijackers TH, Kempen GIJM, Zijlstra GAR, van Rossum E, Koster A, Lima Passos V*, et al.* Effectiveness of a reablement training program for homecare staff on older adults' sedentary behavior: A cluster randomized controlled trial. *J Am Geriatr Soc* 2021;**69**:2566-78. https://doi.org/10.1111/jgs.17286

38. Lewin G, De San Miguel K, Knuiman M, Alan J, Boldy D, Hendrie D*, et al.* A randomised controlled trial of the Home Independence Program, an Australian restorative home-care programme for older adults. *Health Soc Care Community* 2013;**21**:69-78. https://doi.org/10.1111/j.1365-2524.2012.01088.x

39. Wolter A, Stolle C, Roth G, Rothgang H. Does the resident care assessment instrument improve long-term home care? - results of a nation-wide study in Germany. [German]. *Gesundheitswesen* 2013;**75**:29-32. https://doi.org/10.1055/s-0032-1309013

40. Clark F, Azen SP, Zemke R, Jackson J, Carlson M, Mandel D*, et al.* Occupational therapy for independent-living older adults. A randomized controlled trial. *JAMA* 1997;**278**:1321-6. https://doi.org/10.1001/jama.1997.03550160041036

41. Gitlin LN, Winter L, Dennis MP, Corcoran M, Schinfeld S, Hauck WW. A randomized trial of a multicomponent home intervention to reduce functional difficulties in older adults. *J Am Geriatr Soc* 2006;**54**:809-16. https://doi.org/10.1111/j.1532-5415.2006.00703.x

42. Morgan GS, Haase AM, Campbell RM, Ben-Shlomo Y. A pilot randomised controlled trial of physical activity facilitation for older adults: feasibility study findings. *Pilot Feasibility Stud* 2019;**5**:40. https://doi.org/10.1186/s40814-019-0414-9

43. Rockwood K, Stadnyk K, Carver D, MacPherson KM, Beanlands HE, Powell C*, et al.* A clinimetric evaluation of specialized geriatric care for rural dwelling, frail older people. *J Am Geriatr Soc* 2000;**48**:1080-5. https://doi.org/10.1111/j.1532-5415.2000.tb04783.x

44. Bouman A, van Rossum E, Ambergen T, Kempen G, Knipschild P. Effects of a home visiting program for older people with poor health status: a randomized, clinical trial in The Netherlands. *J Am Geriatr Soc* 2008;**56**:397-404. https://doi.org/10.1111/j.1532-5415.2007.01565.x

45. Brettschneider C, Luck T, Fleischer S, Roling G, Beutner K, Luppa M*, et al.* Cost-utility analysis of a preventive home visit program for older adults in Germany. *BMC Health Serv Res* 2015;**15**:141. https://doi.org/10.1186/s12913-015-0817-0

46. Dorresteijn TA, Zijlstra GA, Ambergen AW, Delbaere K, Vlaeyen JW, Kempen GI. Effectiveness of a home-based cognitive behavioral program to manage concerns about falls in community-dwelling, frail older people: results of a randomized controlled trial. *BMC Geriatr* 2016;**16**:2. https://doi.org/10.1186/s12877-015-0177-y

47. Gene Huguet L, Navarro Gonzalez M, Kostov B, Ortega Carmona M, Colungo Francia C, Carpallo Nieto M*, et al.* Pre Frail 80: Multifactorial intervention to prevent progression of pre-frailty to frailty in the elderly. *J Nutr Health Aging* 2018;**22**:1266-74. https://doi.org/10.1007/s12603-018-1089-2

48. Rubenstein LZ, Alessi CA, Josephson KR, Trinidad Hoyl M, Harker JO, Pietruszka FM. A randomized trial of a screening, case finding, and referral system for older veterans in primary care. *J Am Geriatr Soc* 2007;**55**:166-74. https://doi.org/10.1111/j.1532-5415.2007.01044.x

49. Szanton SL, Xue QL, Leff B, Guralnik J, Wolff JL, Tanner EK*, et al.* Effect of a biobehavioral environmental approach on disability among low-income older adults: A randomized clinical trial. *JAMA Intern Med* 2019;**179**:204-11. https://doi.org/10.1001/jamainternmed.2018.6026

50. van Heuvelen MJ, Hochstenbach JB, Brouwer WH, de Greef MH, Zijlstra GA, van Jaarsveld E*, et al.* Differences between participants and non-participants in an RCT on physical activity and psychological interventions for older persons. *Aging Clin Exp Res* 2005;**17**:236-45. https://doi.org/10.1007/BF03324603

51. Jitapunkul S. A randomised controlled trial of regular surveillance in Thai elderly using a simple questionnaire administered by non-professional personnel. *J Med Assoc Thai* 1998;**81**:352-6.

52. Auvinen K, Voutilainen A, Jyrkkä J, Lönnroos E, Mäntyselkä P. Interprofessional medication assessment among home care patients: any impact on functioning? Results from a randomised controlled trial. *BMC Geriatr* 2020;**20**:390-. https://doi.org/10.1186/s12877-020-01796-1

53. Parsons M, Senior H, Kerse N, Chen MH, Jacobs S, Vanderhoorn S*, et al.* Should care managers for older adults be located in primary care? A randomized controlled trial. *J Am Geriatr Soc* 2012;**60**:86-92. https://doi.org/10.1111/j.1532-5415.2011.03763.x

54. Bernabei R, Landi F, Gambassi G, Sgadari A, Zuccala G, Mor V*, et al.* Randomised trial of impact of model of integrated care and case management for older people living in the community. *BMJ* 1998;**316**:1348-51. https://doi.org/10.1136/bmj.316.7141.1348

55. Mann WC, Ottenbacher KJ, Fraas L, Tomita M, Granger CV. Effectiveness of assistive technology and environmental interventions in maintaining independence and reducing home care costs for the frail elderly. A randomized controlled trial. *Arch Fam Med* 1999;**8**:210-7. https://doi.org/10.1001/archfami.8.3.210

56. Bleijenberg N, Drubbel I, Schuurmans MJ, Dam HT, Zuithoff NP, Numans ME*, et al.* Effectiveness of a proactive primary care program on preserving daily functioning of older people: a cluster randomized controlled trial. *J Am Geriatr Soc* 2016;**64**:1779-88. https://doi.org/10.1111/jgs.14325

57. Takahashi PY, Pecina JL, Upatising B, Chaudhry R, Shah ND, Van Houten H*, et al.* A randomized controlled trial of telemonitoring in older adults with multiple health issues to prevent hospitalizations and emergency department visits. *Arch Intern Med* 2012;**172**:773-9. https://doi.org/10.1001/archinternmed.2012.256

58. Walters K, Frost R, Kharicha K, Avgerinou C, Gardner B, Ricciardi F*, et al.* Home-based health promotion for older people with mild frailty: the HomeHealth intervention development and feasibility RCT. *Health Technol Assess* 2017;**21**:1-128. https://doi.org/10.3310/hta21730

59. Cameron ID, Fairhall N, Langron C, Lockwood K, Monaghan N, Aggar C*, et al.* A multifactorial interdisciplinary intervention reduces frailty in older people: randomized trial. *BMC Med* 2013;**11**:65. https://doi.org/10.1186/1741-7015-11-65

60. Serra-Prat M, Sist X, Domenich R, Jurado L, Saiz A, Roces A*, et al.* Effectiveness of an intervention to prevent frailty in pre-frail community-dwelling older people consulting in primary care: a randomised controlled trial. *Age Ageing* 2017;**46**:401-7. https://doi.org/10.1093/ageing/afw242

61. Balaban DJ, Goldfarb NI, Perkel RL, Carlson BL. Follow-up study of an urban family medicine home visit program. *J Fam Pract* 1988;**26**:307-12.

62. Teut M, Schnabel K, Baur R, Kerckhoff A, Reese F, Pilgram N*, et al.* Effects and feasibility of an Integrative Medicine program for geriatric patients-a cluster-randomized pilot study. *Clin Interv Aging* 2013;**8**:953-61. https://doi.org/10.2147/CIA.S45242

63. Hendriksen C, Lund E, Stromgard E. Consequences of assessment and intervention among elderly people: a three year randomised controlled trial. *Br Med J (Clin Res Ed)* 1984;**289**:1522-4. https://doi.org/10.1136/bmj.289.6457.1522

64. Leveille SG, Wagner EH, Davis C, Grothaus L, Wallace J, LoGerfo M*, et al.* Preventing disability and managing chronic illness in frail older adults: a randomized trial of a community-based partnership with primary care. *J Am Geriatr Soc* 1998;**46**:1191-8. https://doi.org/10.1111/j.1532-5415.1998.tb04533.x

65. Ng TP, Feng L, Nyunt MS, Feng L, Niti M, Tan BY*, et al.* Nutritional, physical, cognitive, and combination interventions and frailty reversal among older adults: A randomized controlled trial. *Am J Med* 2015;**128**:1225-36.e1. https://doi.org/10.1016/j.amjmed.2015.06.017

66. Phelan EA, Balderson B, Levine M, Erro JH, Jordan L, Grothaus L*, et al.* Delivering effective primary care to older adults: a randomized, controlled trial of the senior resource team at group health cooperative. *J Am Geriatr Soc* 2007;**55**:1748-56. https://doi.org/10.1111/j.1532-5415.2007.01416.x

67. van Lieshout MRJ, Bleijenberg N, Schuurmans MJ, de Wit NJ. The effectiveness of a PRoactive multicomponent intervention program on disability in independently living older people: A randomized controlled trial. *J Nutr Health Aging* 2018;**22**:1051-9. https://doi.org/10.1007/s12603-018-1101-x

68. van Rossum E, Frederiks CM, Philipsen H, Portengen K, Wiskerke J, Knipschild P. Effects of preventive home visits to elderly people. *BMJ* 1993;**307**:27-32. https://doi.org/10.1136/bmj.307.6895.27

69. Thomas R, Worrall G, Elgar F, Knight J. Can they keep going on their own? A four-year randomized trial of functional assessments of community residents. *Can J Aging* 2007;**26**:379-90. https://doi.org/10.3138/cja.26.4.379

70. Cutchin MP, Coppola S, Talley V, Svihula J, Catellier D, Shank KH. Feasibility and effects of preventive home visits for at-risk older people: design of a randomized controlled trial. *BMC Geriatr* 2009;**9**:54. https://doi.org/10.1186/1471-2318-9-54

71. Gustafson DH, Kornfield R, Mares M-L, Johnston DC, Cody OJ, Yang EF*, et al.* Effect of an eHealth intervention on older adults' quality of life and health-related outcomes: a randomized clinical trial. *J Gen Intern Med* 2021;**37**:521-30. https://doi.org/10.1007/s11606-021-06888-1

72. Alegria M, Frontera W, Cruz-Gonzalez M, Markle SL, Trinh-Shevrin C, Wang Y*, et al.* Effectiveness of a Disability Preventive Intervention for Minority and Immigrant Elders: The Positive Minds-Strong Bodies Randomized Clinical Trial. *Am J Geriatr Psychiatry* 2019;**27**:1299-313. https://doi.org/10.1016/j.jagp.2019.08.008

73. Barenfeld E, Dahlin-Ivanoff S, Wallin L, Gustafsson S. Promoting aging migrants' capabilities: A randomized controlled trial concerning activities of daily living and self-rated health. *AIMS Public Health* 2018;**5**:173-88. https://doi.org/10.3934/publichealth.2018.2.173

74. Borrows A, Holland R. Independent living centre occupational therapy (OT) versus routine community OT. *Int J Ther Rehabil* 2013;**20**:187-94. https://doi.org/10.12968/ijtr.2013.20.4.187

75. Coleman EA, Grothaus LC, Sandhu N, Wagner EH. Chronic Care Clinics: A randomized controlled trial of a model of primary care for frail older adults. *J Am Geriatr Soc* 1999;**47**:775-83. https://doi.org/10.1111/j.1532-5415.1999.tb03832.x

76. Counsell SR, Callahan CM, Clark DO, Tu W, Buttar AB, Stump TE*, et al.* Geriatric care management for low-income seniors: a randomized controlled trial. *JAMA* 2007;**298**:2623-33. https://doi.org/10.1001/jama.298.22.2623

77. de Craen AJ, Gussekloo J, Blauw GJ, Willems CG, Westendorp RG. Randomised controlled trial of unsolicited occupational therapy in community-dwelling elderly people: the LOTIS trial. *PLoS Clin Trials* 2006;**1**:e2. https://doi.org/10.1371/journal.pctr.0010002

78. Fristedt S, Nystedt P, Skogar O. Mobile geriatric teams - a cost-effective way of improving patient safety and reducing traditional healthcare utilization among the frail elderly? A randomized controlled trial. *Clin Interv Aging* 2019;**14**:1911-24. https://doi.org/10.2147/CIA.S208388

79. Gill TM, Baker DI, Gottschalk M, Peduzzi PN, Allore H, Byers A. A program to prevent functional decline in physically frail, elderly persons who live at home. *N Engl J Med* 2002;**347**:1068-74. https://doi.org/10.1056/NEJMoa020423

80. Gustafsson S, Eklund K, Wilhelmson K, Edberg A-K, Johansson B, Kronlöf GH*, et al.* Long-Term Outcome for ADL Following the Health-Promoting RCT—Elderly Persons in the Risk Zone. *Gerontologist* 2013;**53**:654-63. https://doi.org/10.1093/geront/gns121

81. Hogg W, Lemelin J, Dahrouge S, Liddy C, Armstrong CD, Legault F*, et al.* Randomized controlled trial of anticipatory and preventive multidisciplinary team care: for complex patients in a community-based primary care setting. *Can Fam Physician* 2009;**55**:e76-85.

82. Holland SK, Greenberg J, Tidwell L, Malone J, Mullan J, Newcomer R. Community-based health coaching, exercise, and health service utilization. *J Aging Health* 2005;**17**:697-716. https://doi.org/10.1177/0898264305277959

83. Howel D, Moffatt S, Haighton C, Bryant A, Becker F, Steer M*, et al.* Does domiciliary welfare rights advice improve health-related quality of life in independent-living, socio-economically disadvantaged people aged >=60 years? Randomised controlled trial, economic and process evaluations in the North East of England. *PLoS One* 2019;**14**:e0209560. https://doi.org/10.1371/journal.pone.0209560

84. Liimatta H, Lampela P, Laitinen-Parkkonen P, Pitkala KH. Effects of preventive home visits on health-related quality-of-life and mortality in home-dwelling older adults. *Scand J Prim Health Care* 2019;**37**:90-7. https://doi.org/10.1080/02813432.2019.1569372

85. Meng H, Friedman B, Wamsley BR, Mukamel D, Eggert GM. Effect of a consumer-directed voucher and a disease-management-health-promotion nurse intervention on home care use. *Gerontologist* 2005;**45**:167-76. https://doi.org/10.1093/geront/45.2.167

86. Morey MC, Peterson MJ, Pieper CF, Sloane R, Crowley GM, Cowper PA*, et al.* The Veterans Learning to Improve Fitness and Function in Elders Study: a randomized trial of primary care–based physical activity counseling for older men. *J Am Geriatr Soc* 2009;**57**:1166-74. https://doi.org/10.1111/j.1532-5415.2009.02301.x

87. Siemonsma PC, Blom JW, Hofstetter H, van Hespen ATH, Gussekloo J, Drewes YM*, et al.* The effectiveness of functional task exercise and physical therapy as prevention of functional decline in community dwelling older people with complex health problems. *BMC Geriatr* 2018;**18**:164. https://doi.org/10.1186/s12877-018-0859-3

88. Vass M, Avlund K, Lauridsen J, Hendriksen C. Feasible model for prevention of functional decline in older people: municipality-randomized, controlled trial. *J Am Geriatr Soc* 2005;**53**:563-8. https://doi.org/10.1111/j.1532-5415.2005.53201.x

89. Williams EI, Greenwell J, Groom LM. The care of people over 75 years old after discharge from hospital: an evaluation of timetabled visiting by Health Visitor Assistants. *J Public Health Med* 1992;**14**:138-44. https://doi.org/10.1093/oxfordjournals.pubmed.a042711

90. Yamada Y, Ikegami N. Preventive home visits for community- dwelling frail elderly people based on minimum data set-home care: randomized controlled trial. *Geriatr Gerontol Int* 2003;**3**:236–42. https://doi.org/10.1111/j.1444-1586.2003.00103.x